<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102068</article-id><article-id pub-id-type="doi">10.7554/eLife.102068</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102068.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>β-Glucan reprograms alveolar macrophages via neutrophil/IFNγ axis in a murine model of lung injury</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prevel</surname><given-names>Renaud</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pernet</surname><given-names>Erwan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Kim A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0299-7417</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sadek</surname><given-names>Abderrahmane</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sadeghi</surname><given-names>Mina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lapshina</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jurado</surname><given-names>Leonardo F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kristof</surname><given-names>Arnold S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Moumni</surname><given-names>Mohieddine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Poschmann</surname><given-names>Jeremie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9613-5297</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Divangahi</surname><given-names>Maziar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1254-6110</contrib-id><email>maziar.divangahi@mcgill.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>Department of Medicine, Meakins-Christie Laboratories, Research Institute McGill University Health Centre, McGill University</institution></institution-wrap><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01165k395</institution-id><institution>INSERM, Nantes Université, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, ITUN</institution></institution-wrap><addr-line><named-content content-type="city">Nantes</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cnscd67</institution-id><institution>Biotechnology and Bioresources Valorization Laboratory, Biology Department, Faculty of Sciences, Moulay Ismail University of Meknès</institution></institution-wrap><addr-line><named-content content-type="city">Meknès</named-content></addr-line><country>Morocco</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>Department of Microbiology and Immunology, Meakins-Christie Laboratories, Research Institute McGill University Health Centre, McGill University</institution></institution-wrap><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>Department of Pathology, Research Institute McGill University Health Centre, McGill University</institution></institution-wrap><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff><aff id="aff6"><label>6</label><institution>McGill International TB Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kaufmann</surname><given-names>Eva</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queen's University</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028qa3n13</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP102068</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-08-08"><day>08</day><month>08</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.02.610842"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-02"><day>02</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102068.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-17"><day>17</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102068.2"/></event></pub-history><permissions><copyright-statement>© 2024, Prevel et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Prevel et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102068-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102068-figures-v1.pdf"/><abstract><p>Alveolar macrophages (AMs) reside in the lower airways and play a crucial role in lung health and response to sterile inflammation and infections. AMs possess remarkable adaptability to different environmental challenges that can persist through their memory capacity (trained immunity). β-Glucan has been characterized as a potent inducer of central trained immunity by reprogramming haematopoietic stem cells in the bone marrow. In the present study, we show that systemic administration of β-glucan in mice induces peripheral trained immunity by reprogramming AMs in the lungs, in a Dectin1-independent manner. We furthermore demonstrate that AM reprogramming at both the transcriptional and metabolic levels exacerbate lung injury following bacterial (lipopolysaccharide) or viral (polyI:C) challenges via a neutrophil/IFN-γ-dependent manner. These findings identify an additional facet of β-glucan in trained immunity involving AM reprogramming and shed light on the potential detrimental effects of trained immunity.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>trained immunity</kwd><kwd>acute lung injury</kwd><kwd>β-glucan</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>168885</award-id><principal-award-recipient><name><surname>Divangahi</surname><given-names>Maziar</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>MM1174910</award-id><principal-award-recipient><name><surname>Divangahi</surname><given-names>Maziar</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000156</institution-id><institution>Fonds de Recherche du Québec - Santé</institution></institution-wrap></funding-source><award-id>Award</award-id><principal-award-recipient><name><surname>Divangahi</surname><given-names>Maziar</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000156</institution-id><institution>Fonds de Recherche du Québec - Santé</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Pernet</surname><given-names>Erwan</given-names></name><name><surname>Prevel</surname><given-names>Renaud</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000188</institution-id><institution>Royal Society of Canada</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Divangahi</surname><given-names>Maziar</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>β-Glucan-mediated trained immunity activates alveolar macrophages which exacerbates acute lung injury induced by LPS.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The lungs represent a significant infective niche for numerous infectious agents. However, severe pulmonary disease is increasingly being associated with immune-mediated responses rather than direct damage of invading microbes (<xref ref-type="bibr" rid="bib69">Xiao et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Gustine and Jones, 2021</xref>). Among the various triggers of immunopathology, lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, is a potent inducer of systemic inflammation via activation of Toll-like receptor 4 (TLR4) (<xref ref-type="bibr" rid="bib46">Opal, 2010</xref>). Excessive inflammation associated with LPS can cause acute lung injury (ALI), a severe inflammatory condition of the lungs characterized by alveolar damage, edema, and impaired gas exchange leading to organ dysfunction, and ultimately, mortality (<xref ref-type="bibr" rid="bib70">Xu et al., 2024</xref>; <xref ref-type="bibr" rid="bib15">Gill et al., 2015</xref>). Thus, the magnitude of inflammatory responses must be regulated to resolve infections while preventing collateral tissue damage. Understanding the mechanisms underlying the regulation of inflammation in ALI is essential for the development of effective therapeutic interventions. Key players in this regulatory network include various immune cells, cytokines, and signalling pathways, which collectively modulate the intensity and duration of inflammatory responses. Dysregulation of these mechanisms can lead to either persistent inflammation or immunosuppression, both of which contribute to the pathogenesis of sepsis (<xref ref-type="bibr" rid="bib59">Sun et al., 2023</xref>; <xref ref-type="bibr" rid="bib28">Kumar, 2020</xref>; <xref ref-type="bibr" rid="bib76">Zhou and Liao, 2021</xref>).</p><p>The constant exposure of the lungs to a non-sterile environment leads to the development of a unique immunity by eliminating inhaled foreign particles while minimizing inflammatory-mediated tissue damage. Resident alveolar macrophages (AMs) serve a crucial regulatory function to maintain the delicate balance between inflammation and protecting lung tissue from damage (<xref ref-type="bibr" rid="bib55">Schneider et al., 2014</xref>). AMs primarily originate from fetal liver monocytes that colonize the airways during development and subsequently maintain their population through local self-renewal. The pulmonary AM pool can also be replenished beyond the neonatal period by bone marrow-derived monocytes following different stimuli (<xref ref-type="bibr" rid="bib37">Misharin et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2022</xref>). Due to their strategic location, AMs serve as vigilant sentinels, protecting the airways from invading pathogens and pollutants. They play a pivotal role in orchestrating both the initiation and resolution of immune responses within the lung microenvironment (<xref ref-type="bibr" rid="bib17">Guilliams et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Hussell and Bell, 2014</xref>).</p><p>Adaptations in innate immune cells are diverse with substantial plasticity to various insults that can be maintained resulting in enhanced (trained immunity) or reduced (tolerance) inflammatory responses to a second stimuli (<xref ref-type="bibr" rid="bib10">Divangahi et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Netea et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Netea et al., 2016</xref>). Trained immunity is mediated via long-term metabolic reprogramming and epigenetic modifications, which can be induced by various stimuli such as the attenuated mycobacteria Bacille Calmette-Guérin (BCG) or β-glucan (a polysaccharidic component of fungi cell wall) (<xref ref-type="bibr" rid="bib10">Divangahi et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Camilli et al., 2018</xref>). BCG and β-glucan are able to train monocytes and neutrophils with beneficial impact in cancer or infections via the reprogramming of haematopoietic stem cells (HSCs) within the bone marrow (<xref ref-type="bibr" rid="bib39">Moorlag et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Roquilly et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Broquet et al., 2024</xref>; <xref ref-type="bibr" rid="bib27">Khan et al., 2025</xref>). However, there are substantial knowledge gaps in our understanding of trained immunity within tissue-resident macrophages and its regulatory role in maintaining tissue homeostasis under stress conditions. For instance, while the initial LPS stimulation of macrophages induces a strong inflammatory responses via TLR-4, restimulation with LPS generates tolerance in these macrophages (<xref ref-type="bibr" rid="bib13">Foster et al., 2007</xref>). Thus, the epigenetic reprogramming of innate immune cells and their subsequent response depends on two signals: the initial training agent and the nature of the second stimuli at an inflammatory site. Here we showed that systemic administration of β-glucan can reprogram AMs in the lungs via neutrophil/type II IFN axis but independent of Dectin-1 signalling. The unique transcriptomic and metabolic profile of AMs render them hyperresponsive to both bacterial and viral stimulation causing dysregulated inflammatory responses with pulmonary damage. The differences in the systemic basal levels of β-glucan in sepsis patients as well as the pulmonary levels of IFNγ can be major factors in determining the hyperresponsiveness in sepsis patients and can be potentially targeted for therapy.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>β-Glucan-mediated trained immunity aggravates LPS-induced ALI</title><p>To investigate whether systemic administration of β-glucan induces trained immunity within the lung, we sought to assess its impact on ALI triggered by LPS treatment. We initially evaluated the consequences of β-glucan-mediated training on ALI by administering LPS 7 days after training (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). ALI assessment conducted 24 hr post-LPS instillation did not reveal any discernible distinctions attributable to the initial i.p. β-glucan injection. However, ALI was notably exacerbated in mice that had undergone β-glucan training upon subsequent LPS stimulation as demonstrated non-invasively by lung microCT scanners with regard to the increased proportion of poorly or non-aerated lung segment and to a significant increase in Hounsfield units (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Hounsfield units reflect a coefficient of tissue attenuation and, by extrapolation, tissue composition. Consistent findings were corroborated through two complementary invasive evaluations of ALI. Specifically, the heightened alveolar-capillary permeability following LPS instillation in β-glucan-trained mice was substantiated by elevated lung Evans blue dye concentrations (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Histological examination further unveiled a spectrum of notable alterations following LPS instillation, including cellular infiltration, thickened alveolar walls, and the formation of hyaline membranes, observed in β-glucan-trained mice and not PBS controls (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We additionally monitored weight loss following LPS instillation. ALI-induced inflammation peaks at 24 hr, reflected in the weight loss of the mice which drops nearly 10% within a day. While there were no differences in weight loss between control and β-glucan-treated mice at this timepoint, we observed that β-glucan mice exhibited a delayed recovery period given they did not return to their original weight by day 4, as opposed to control mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>β-Glucan-mediated trained immunity increases lipopolysaccharide (LPS)-induced acute lung injury (ALI).</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training 7 days before LPS-induced ALI model. Experiments were performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) WT mice. (<bold>B</bold>) Lung micro-CT scan, percentage of poorly or non-aerated lung and average lung Hounsfield unit. (<bold>C</bold>) Alveolar capillary membrane permeability assessed by lung Evans blue dye concentration. (<bold>D</bold>) Lung histology after staining with haematoxylin and eosin (Scale bar = 200 μm). (<bold>E</bold>) Quantification of bronchoalveolar lavage (BAL) neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>F–H</bold>) BAL chemokine and pro-inflammatory cytokines concentrations (left to right) (CXCL1: chemokine C-X-C motif ligand 1, IL-6: interleukin-6, and TNF: tumour necrosis factor). (<bold>I</bold>) Quantification of BAL alveolar macrophages frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>+</sup>, Siglec-F<sup>+</sup>). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, ***p &lt; 0.001. Schematics created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Individual measurements, cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Weight loss following lipopolysaccharide (LPS) instillation.</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training 7 days before LPS-induced acute lung injury (ALI) model for weight loss monitoring. (<bold>B</bold>) Weight loss curve post-LPS instillation (<italic>n</italic> = 10). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Animal weights overtime post-LPS.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Alveolar macrophage (AM) characterization in β-glucan-treated mice.</title><p>(<bold>A</bold>) CD11b expression on CD11c<sup>+</sup>SiglecF<sup>+</sup> cells in the bronchoalveolar lavage (BAL) (<italic>n</italic> = 4). (<bold>B</bold>) Expression of AM-associated marker (left to right: MHCII, F4/80, CD169, CD64, CD80) on CD11c<sup>+</sup>SiglecF<sup>+</sup> cells in the BAL (<italic>n</italic> = 5). Data were analysed using unpaired <italic>t</italic>-test and one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Cell frequencies.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Long-term effects of β-glucan-mediated trained immunity on lipopolysaccharide (LPS)-induced acute lung injury (ALI).</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training 28 days before LPS-induced ALI model. Experiments were performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) WT mice. (<bold>B</bold>) Alveolar capillary membrane permeability assessed by lung Evans blue dye concentration. (<bold>C</bold>) Lung histology after staining with haematoxylin and eosin (Scale bar = 200 μm). (<bold>D</bold>) Bronchoalveolar lavage (BAL) chemokine C-X-C motif ligand 1 (CXCL1) concentration (left) and pro-inflammatory cytokines (IL-6: interleukin-6 (middle) and TNF: tumour necrosis factor (right)). (<bold>E</bold>) Quantification of BAL neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>F</bold>) Quantification of BAL alveolar macrophages frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>+</sup>, Siglec-F<sup>+</sup>). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Individual measurements, cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Long-term effects of β-glucan-mediated trained immunity on alveolar macrophages (AMs).</title><p>(<bold>A</bold>) Schematic of control (i.p. PBS, white bars) or 28 days β-glucan-trained (i.p. β-glucan, green bars) AMs collected from adult WT mice ex vivo stimulation with lipopolysaccharide (LPS). (<bold>B</bold>) Chemokine C-X-C motif ligand 1 (CXCL1) and tumour necrosis factor (TNF) concentrations after ex vivo LPS stimulation. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. **p &lt; 0.01 Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Cytokine concentrations.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>β-Glucan-mediated trained immunity increases poly(I:C)-induced acute lung injury (ALI).</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training 7 days before poly(I:C)-induced ALI model. Experiments were performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) WT mice. (<bold>B</bold>) Alveolar capillary membrane permeability assessed by lung Evans blue dye concentration. (<bold>C</bold>) Lung histology after staining with haematoxylin and eosin (Scale bar = 200 μm). (<bold>D</bold>) Bronchoalveolar lavage (BAL) chemokine C-X-C motif ligand 1 (CXCL1) concentration (left) and pro-inflammatory cytokines (IL-6: interleukin-6 (middle) and TNF: tumour necrosis factor (right)). (<bold>E</bold>) Quantification of BAL neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>F</bold>) Quantification of BAL alveolar macrophages frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>+</sup>, Siglec-F<sup>+</sup>). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig1s5sdata1"><label>Figure 1—figure supplement 5—source data 1.</label><caption><title>Individual measurements, cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig1-figsupp5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig1-figsupp5-v1.tif"/></fig></fig-group><p>The increased cell infiltration 24 hr after LPS instillation in β-glucan-treated mice was due to a significant recruitment of neutrophils, as assessed in the bronchoalveolar lavage (BAL; CD11b<sup>+</sup>Ly6G<sup>+</sup>). Strikingly, the frequency and total numbers of neutrophils was doubled in the β-glucan-treated mice, after LPS administration (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Concomitant with the increased neutrophil recruitment, CXCL1 was significantly increased in β-glucan-treated mice when compared to control mice after LPS treatment (<xref ref-type="fig" rid="fig1">Figure 1F</xref>; <xref ref-type="bibr" rid="bib66">Wengner et al., 2008</xref>). Amplified ALI in β-glucan-trained mice was also associated with increased proinflammatory cytokines (IL-6 and TNF) (<xref ref-type="fig" rid="fig1">Figure 1G, H</xref>). As AMs are major producers of CXCL1, IL6, and TNF, we next assessed whether β-glucan increased the proportion or number of AMs and found no significant differences between naive and β-glucan-trained mice (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). There were also no changes in the frequency of CD11b<sup>+</sup> AMs at baseline and post-LPS instillation between β-glucan-treated and control mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). This suggests that β-glucan does not induce the expansion of monocyte-derived AMs. To further characterize AM phenotype following β-glucan, we assessed several AM-associated cell surface markers and found no differences in expression of MHCII, F4/80, CD169, and CD69 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Interestingly, β-glucan enhanced the frequency of CD80<sup>+</sup> AMs, a costimulatory molecule associated with activation and pro-inflammatory responses (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>; <xref ref-type="bibr" rid="bib6">Burastero et al., 1999</xref>). Thus, the increased cytokine production was not due to an increased number of AMs, but rather intrinsic functional changes.</p><p>Next, we examined whether the effects of β-glucan-induced immune training persisted in ALI severity. To do so, we administered β-glucan or PBS (control) in mice and after 28 days challenged them with LPS (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). Similar to the 7-day timeframe of β-glucan training, there was increased endothelial permeability of the lungs, and increased immunopathology (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B, C</xref>) in 28 days β-glucan-trained mice challenged with LPS. This increased ALI in β-glucan-treated mice after 28 days was associated with a higher concentration of CXCL1, IL-6, and TNF and increased neutrophil infiltration in BAL (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3D, E</xref>) following LPS instillation. The frequency and number of AMs were not changed between groups (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3F</xref>). Increased production of cytokines was also observed upon ex vivo stimulation of AMs isolated from treated mice 28 day post-β-glucan (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Thus, the intrinsic functional changes in AMs suggest that the exacerbation of ALI induced by β-glucan triggered a long-term reprogramming of immune cells rather than an additive effect of lingering inflammation from β-glucan injection. To assess whether this response was specific to bacterial LPS or viral agonists can cause similar responses, we next challenged β-glucan-trained mice with a TLR-3 agonist (poly(I:C)) (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5A</xref>). Similar to the LPS-model, β-glucan-treated mice had heightened poly(I:C)-induced ALI shown via increased alveolar-capillary permeability, tissue damage (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5B, C</xref>). Pro-inflammatory cytokines CXCL1 and IL-6 were also increased while TNF remains unchanged following challenge suggesting differing cytokine profiles between LPS and poly(I:C)-induced ALI (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5D</xref>). However, β-glucan-treated mice similarly had increased neutrophil infiltration following poly(I:C) instillation (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5E</xref>). The number of AMs was also unchanged among groups (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5F</xref>). Collectively, these results suggest that systemic β-glucan can maintain a long-term reprogramming in AMs promoting ALI.</p></sec><sec id="s2-2"><title>β-Glucan augmented ALI is mediated via AM</title><p>Although there were no differences in the frequency or absolute number of AMs between β-glucan-treated and control mice, the early heightened response with increased CXCL1 production and the recruitment of neutrophils indicate that the AMs are engaged in the exacerbation of ALI induced by β-glucan. To further characterize the role of these cells in ALI, we locally depleted AMs using intranasally administered clodronate liposomes 2 days before performing the LPS instillation, which is at its peak of AM depletion (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Depletion of AMs significantly reduced the production of cytokines TNF, IL-6, and CXCL1 and the recruitment of neutrophils in BAL, which abolished the β-glucan-induced ALI (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Systemic administration of β-glucan enhances acute lung injury (ALI) via alveolar macrophages (AMs).</title><p>(<bold>A</bold>) Schematic of the clodronate-mediated AMs depletion experiments, performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) WT mice. (<bold>B</bold>) Alveolar capillary membrane permeability assessed by lung Evans blue dye concentration. (<bold>C</bold>) Quantification of bronchoalveolar lavage (BAL) neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>D</bold>) BAL chemokine C-X-C motif ligand 1 (CXCL1) and pro-inflammatory cytokines (IL-6: interleukin-6 and TNF: tumour necrosis factor) concentrations. (<bold>E</bold>) Schematic of the β-glucan-induced training and lipopolysaccharide (LPS)-induced ALI model in sex- and age-matched 6-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) <italic>Csf2rb<sup>-/-</sup></italic> mice. (<bold>F</bold>) BAL total protein concentration. (<bold>G</bold>) Quantification of BAL neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>H</bold>) BAL CXCL1, IL-6, and TNF concentrations. (<bold>I</bold>) Schematic of the adoptive transfer of control (i.p. PBS, white bars) or β-glucan-trained (i.p. β-glucan, green bars) AMs collected from adult WT mice to 2 days old <italic>Csf2rb<sup>−/−</sup></italic> mice. LPS-induced ALI was performed 6 weeks after adoptive transfer. (<bold>J</bold>) BAL total protein concentration. (<bold>K</bold>) Quantification of BAL neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>L</bold>) BAL CXCL1, IL-6, and TNF concentrations. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. Schematics created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/05zbjio">BioRender.com</ext-link>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Individual measurements, cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig2-v1.tif"/></fig><p>To further confirm that tissue-resident AMs are responsible for the increased β-glucan-induced ALI, we used <italic>Csf2rb<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), which do not naturally develop AMs throughout their lifespan but maintain regular levels of bone marrow-derived macrophages and interstitial macrophages (<xref ref-type="bibr" rid="bib53">Robb et al., 1995</xref>). Similar to the AM depletion, the production of cytokines and neutrophil recruitment in BAL was similar between β-glucan-treated and control <italic>Csf2rb<sup>−/−</sup></italic> mice after LPS administration. Importantly, there was no difference in ALI, as similar levels of proteins were measured in the BAL of β-glucan-treated and control <italic>Csf2rb<sup>−/−</sup></italic> after the LPS challenge (<xref ref-type="fig" rid="fig2">Figure 2F–H</xref>).</p><p>To complement these loss-of-function experiments with a gain-of-function, we adoptively transferred AMs from adult WT control (PBS) or trained (β-glucan) mice to day 2 <italic>Csf2rb<sup>−/−</sup></italic> neonate mice (<xref ref-type="fig" rid="fig2">Figure 2I</xref>) and after 6 weeks challenged these mice with LPS. Remarkably, mice replenished with AMs from β-glucan-trained mice displayed an increased in production of inflammatory cytokines and the recruitment of neutrophils into the BAL (<xref ref-type="fig" rid="fig2">Figure 2K, L</xref>). This was associated with increased ALI as they had higher protein levels in their BAL compared to mice who received control AMs (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). Collectively, our data demonstrate that the exacerbation of LPS-induced ALI in β-glucan-trained mice is mediated through AMs, mainly via functional reprogramming rather than a change in the proportion or number of AMs.</p></sec><sec id="s2-3"><title>β-Glucan reprograms AM</title><p>Our findings indicate that β-glucan reprograms AMs causing an increased response to LPS and subsequently enhanced ALI. To test this hypothesis, we investigated the transcriptional state of AMs after 7 days training with β-glucan in vivo, which were then stimulated with/without LPS ex vivo LPS. The rationale for using an ex vivo system was to ensure that AMs are uniformly stimulated with LPS (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>β-Glucan reprograms alveolar macrophages (AMs).</title><p>(<bold>A</bold>) Schematic of control (i.p. PBS) or β-glucan-trained (i.p. β-glucan) AMs collected from adult WT mice ex vivo stimulation with lipopolysaccharide (LPS) (LPS−: unstimulated, LPS+: stimulated in RNA-seq analysis). (<bold>B</bold>) Discovery plot. (<bold>C</bold>) AM differential expression of genes in response to β-glucan training. (<bold>D</bold>) Gene ontology in response to β-glucan training. (<bold>E</bold>) Gene set enrichment analysis (GSEA) in response to β-glucan training. (<bold>F</bold>) AM differential expression of genes in response to LPS stimulation. (<bold>G</bold>) Gene ontology in response to LPS stimulation. (<bold>H</bold>) GSEA in response to LPS stimulation. (<bold>I</bold>) AM gene expression in response to LPS in β-glucan-trained AMs. (<bold>J</bold>) Examples of genes expression in response to LPS in control versus β-glucan-trained AMs. (<bold>K</bold>) Chemokine C-X-C motif ligand 1 (CXCL1) and tumour necrosis factor (TNF) concentrations after ex vivo LPS stimulation. (<bold>L</bold>) GSEA of oxidative phosphorylation (left) and glycolysis (right) pathways according to β-glucan-training in unstimulated (LPS−) and LPS stimulated (LPS+) AMs. (<bold>M</bold>) Evaluation of AM metabolism: basal respiration (upper left), ATP production (upper right), extracellular acidification rate (ECAR, lower left), and oxygen consumption rate (OCR, lower right). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. **p &lt; 0.01, ***p &lt; 0.001. Schematics created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Cytokine concentrations and Seahorse measurements.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Expression of virus response genes in β-glucan-trained alveolar macrophages (AMs).</title><p>Schematic of control and β-glucan-trained AMs collected from adult WT mice ex vivo stimulation with lipopolysaccharide (LPS). Differential expression of viral defense genes in response to LPS in β-glucan-trained AMs. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Principal component analysis of all expressed genes across the four conditions revealed that control and β-glucan-trained AMs had distinct transcriptional profiles (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). More precisely, the four different conditions explained the largest variance as they spread out across the first principal component (PC), while the variation within replicates was associated to the second and third PC. Next, we investigated the effect of β-glucan-trained AMs by comparing the differential gene expression between control and β-glucan-treated mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). We found 88 differentially expressed genes (32 upregulated and 56 downregulated, with a false discovery rate (FDR) adjusted p-value &lt;0.05 and a log<sub>2</sub>fold-change cut-off of 1). Despite that only few genes were differentially expressed, gene ontology analysis indicated a strong enrichment of genes involved in innate immune response and defense response to virus (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Interestingly, LPS response genes were downregulated in β-glucan-treated mice suggesting that, in response to β-glucan, the LPS response pathway is attenuated or less activated. Gene set enrichment analysis (GSEA) additionally revealed an increase of genes involved in IFNα but a significant decrease of genes involved in TNF signalling (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><p>Next, we explored how ex vivo stimulated AMs responded to LPS using the same differential gene expression analysis. LPS altered the expression of 525 genes (FDR &gt;0.05 log<sub>2</sub>FC &gt;1.5) with the up regulation of 438 genes including numerous pro-inflammatory genes (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). As expected, gene ontology analyses revealed that these genes were involved in cellular response to LPS, inhibition of viral genome replication, production of interleukin-1β and cellular response to IL-1 (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Additional analysis of GSEA indicated upregulation of genes involved in TNF signalling (<xref ref-type="fig" rid="fig3">Figure 3H</xref>), indicating that LPS and β-glucan both induce interferon responses but have opposite effects on the TNF response pathway.</p><p>To delineate how β-glucan training of AMs may affect the subsequent response to LPS, we then compared the fold change of gene expression in response to LPS stimulation between β-glucan-trained and -untrained AMs. Notably, we observed an upregulation of genes associated with the LPS response (depicted in blue) in the β-glucan-trained group (<xref ref-type="fig" rid="fig3">Figure 3I</xref>). This heightened response included a significant increase in the expression of IL-6, IL-1, TNF, and other genes (<xref ref-type="fig" rid="fig3">Figure 3I, J</xref>). This increased response to LPS by β-glucan-trained AMs was confirmed at the protein level as they exhibited increased ex vivo production of CXCL1 and TNF (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). Such an increased response to LPS was also obtained in AMs after 28 days β-glucan training (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). We also observed similar trends in genes associated with the defense response to viruses which is in line with our findings showing an increased ALI to poly(I:C) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Taken together, β-glucan reprograms AMs to respond robustly to LPS stimulation.</p><p>As trained immunity is associated with metabolic rewiring, we next assessed if β-glucan-induced training modified the AM’s metabolic state. Genes involved in both oxidative phosphorylation and glycolysis were upregulated during response to LPS in β-glucan-trained AMs compared to untrained AMs but not at the steady state (<xref ref-type="fig" rid="fig3">Figure 3L</xref>). The Seahorse assay showed while only mitochondrial respiration was increased in β-glucan-trained AMs at the steady state, both mitochondrial respiration and glycolysis were increased during the response to LPS in β-glucan-trained AMs, (<xref ref-type="fig" rid="fig3">Figure 3M</xref>). Taken together, β-glucan functionally reprograms AMs by rewiring their transcriptomic and metabolic states.</p></sec><sec id="s2-4"><title>IFNγ signalling and neutrophils are required for AM reprogramming</title><p>Dectin-1 is the receptor that recognizes β-glucan and is involved in mediating the biological effects of β-glucan-induced training in most cell types (<xref ref-type="bibr" rid="bib7">Camilli et al., 2018</xref>). To assess the role of Dectin-1 in β-glucan increased LPS-induced ALI, we used the same experimental setup using Dectin-1-deficient mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Surprisingly, the increased neutrophil infiltration and pro-inflammatory cytokine production in BAL were maintained in β-glucan-treated <italic>Dectin-1<sup>−/−</sup></italic> mice and there was no change in the AM numbers (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B–D</xref>). To determine the effect of <italic>Clec7a</italic> (Dectin-1) on β-glucan-induced AM function, <italic>Dectin-1<sup>−/−</sup></italic> mice were treated with β-glucan and after 7 days AMs were cultured and stimulated ex vivo with LPS (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Similar to wild-type AMs, the production of pro-inflammatory cytokines CXCL1 and TNF was increased in β-glucan-trained Dectin1-deficient AMs after LPS stimulation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). This indicates that β-glucan-induced AMs reprogramming is <italic>Clec7a</italic>-independent and that AMs are trained via a different signalling pathway. Since we observed type I IFN gene expression is increased in AMs after β-glucan treatment (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) and type I IFN was previously reported to be involved in AMs training (<xref ref-type="bibr" rid="bib74">Zahalka et al., 2022</xref>), we next assessed the impact of β-glucan on AMs reprogramming in <italic>Ifnar<sup>−/−</sup></italic> mice, which lack type I IFN signalling (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). Similar to Dectin-1-deficient mice, increased production of pro-inflammatory cytokines in response to LPS by β-glucan-treated <italic>Ifnar<sup>−/−</sup></italic> AMs was maintained, demonstrating that β-glucan-induced AMs reprogramming is type I IFN independent (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>).</p><p>Considering recent studies suggesting type II IFN can train AMs following BCG (<xref ref-type="bibr" rid="bib63">Tran et al., 2024</xref>) or adenoviral infection (<xref ref-type="bibr" rid="bib73">Yao et al., 2018</xref>), using <italic>IfngR<sup>−/−</sup></italic> mice we next investigated if type II IFN is involved in β-glucan-induced exacerbation of ALI (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast to <italic>Dectin1<sup>−/−</sup></italic> or <italic>Ifnar<sup>−/−</sup></italic> mice, the increased neutrophils recruitment, inflammatory cytokines production, and ALI were abolished in β-glucan-trained <italic>IfngR<sup>−/−</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>). To investigate the role of type II IFN signalling in β-glucan-induced reprogramming of AMs, we performed ex vivo LPS stimulation on β-glucan-trained <italic>IfngR<sup>−/−</sup></italic> AMs (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The increase of inflammatory cytokines in response to LPS by β-glucan-trained AMs was abolished (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), suggesting that training of AM by β-glucan is IFNγ dependent.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>IFNγ and neutrophils are required in β-glucan-mediated alveolar macrophage (AM) reprogramming.</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training and lipopolysaccharide (LPS)-induced acute lung injury (ALI) model. Experiments were performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) <italic>IfngR<sup>−/−</sup></italic> mice. (<bold>B</bold>) Alveolar capillary membrane permeability assessed by lung Evans blue dye concentration. (<bold>C</bold>) Quantification of bronchoalveolar lavage (BAL) neutrophils proportion (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>D</bold>) BAL chemokine C-X-C motif ligand 1 (CXCL1) concentration (left) and pro-inflammatory cytokines (IL-6: interleukin-6 (middle) and TNF: tumour necrosis factor (right)) concentrations. (<bold>E</bold>) Schematic of control (i.p. PBS, white bars) or β-glucan-trained (i.p. β-glucan, green bars) AMs collected from adult <italic>IfngR<sup>−/−</sup></italic> mice ex vivo stimulation with LPS. (<bold>F</bold>) Chemokine C-X-C motif ligand 1 (CXCL1) and tumour necrosis factor (TNF) concentrations after ex vivo LPS stimulation. (<bold>G</bold>) Schematic of the analysis of the effect of i.p. β-glucan injection on interferon-γ (IFNγ) production and neutrophils expansion before (white bars) and days 1, 3, 5, and 7 post-injection (green bars). (<bold>H</bold>) BAL IFNγ concentrations. (<bold>I</bold>) Quantification of BAL neutrophils proportion (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>J</bold>) Quantification of lung neutrophils proportion (left) and absolute count (right). (<bold>K</bold>) Schematic of control (i.p. PBS, white bars) or β-glucan-trained (i.p. β-glucan, green bars) AMs ex vivo stimulation with 50 ng/ml LPS. AMs were collected from control (i.p. injection of isotypes), neutrophils depleted (i.p. injection of anti-Ly6G antibodies), or IFNγ antibody-depleted (i.p. injection of anti-IFNγ antibodies) adult WT mice. (<bold>L</bold>) CXCL1 and TNF concentrations after ex vivo LPS stimulation. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, ***p &lt; 0.001. Schematics created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Individual measurements, cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>β-Glucan-aggravated acute lung injury (ALI) is independent of Dectin-1.</title><p>(<bold>A</bold>) Schematic of the β-glucan-induced training 7 days before lipopolysaccharide (LPS)-induced ALI model. Experiments were performed in sex- and age-matched 10- to 12-week-old control (i.p. PBS, white bars) and trained (i.p. β-glucan, green bars) <italic>Dectin1<sup>−/−</sup></italic> mice. (<bold>B</bold>) Bronchoalveolar lavage (BAL) chemokine C-X-C motif ligand 1 (CXCL1) concentration (left) and pro-inflammatory cytokines (IL-6: interleukin-6 (middle) and TNF: tumour necrosis factor (right)). (<bold>C</bold>) Quantification of BAL neutrophils frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>−</sup>, Siglec-F<sup>−</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>). (<bold>D</bold>) Quantification of BAL alveolar macrophages frequency (left) and absolute count (right) (gated on single live cells, CD45.2<sup>+</sup>, CD11c<sup>+</sup>, Siglec-F<sup>+</sup>). Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. *p &lt; 0.05, **p &lt; 0.01. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Cytokine concentrations, cell frequencies and cell numbers.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>β-Glucan-mediated alveolar macrophage (AM) reprogramming is independent of Dectin-1.</title><p>(<bold>A</bold>) Schematic of control (i.p. PBS, white bars) β-glucan-trained (i.p. β-glucan, green bars) AMs collected from adult <italic>Dectin1<sup>−/−</sup></italic> mice ex vivo stimulation with lipopolysaccharide (LPS). (<bold>B</bold>) Chemokine C-X-C motif ligand 1 (CXCL1) and tumour necrosis factor (TNF) concentrations after ex vivo LPS stimulation. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. ***p &lt; 0.001. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Cytokine concentrations.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>β-Glucan-mediated alveolar macrophage (AM) reprogramming is independent of type I interferon signalling.</title><p>(<bold>A</bold>) Schematic of control (i.p. PBS, white bars) β-glucan-trained (i.p. β-glucan, green bars) AMs collected from adult <italic>Ifnar<sup>−/−</sup></italic> mice ex vivo stimulation with lipopolysaccharide (LPS). (<bold>B</bold>) Chemokine C-X-C motif ligand 1 (CXCL1) and tumour necrosis factor (TNF) concentrations after ex vivo LPS stimulation. Data were analysed using one-way ANOVA followed by Dunn’s multiple comparisons test. **p &lt; 0.01, ***p &lt; 0.001. Schematic created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/qwohzw3">BioRender.com</ext-link>.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Cytokine concentrations.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102068-fig4-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Considering the concentration of IFNγ was significantly increased in BAL at day 1 post- β-glucan administration, which was associated with the increased number of neutrophils (<xref ref-type="fig" rid="fig4">Figure 4G–J</xref>), we next assess the direct role of IFNγ in training of AMs by β-glucan. We selectively depleted IFNγ prior to β-glucan administration in vivo (<xref ref-type="fig" rid="fig4">Figure 4K</xref>), and found the production of inflammatory cytokines (CXCL1 and TNF) was significantly reduced in β-glucan-trained AMs. Similarly, the depletion of neutrophils prior to β-glucan treatment in mice resulted in significant reduction in inflammatory cytokines in β-glucan-trained AMs (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). These findings indicate that β-glucan reprograms AMs via IFNγ- and neutrophil-dependent manner.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The evolving field of trained immunity has challenged the boundaries we once drew to discern between the innate and adaptive immune systems. The discovery that the innate immune system can be ‘trained’ to retain memory-like features has provided novel avenues for prophylactic and therapeutic strategies. The use of an adjuvant like β-glucan has been investigated as an anti-infection agent in acute infections or inflammatory conditions (<xref ref-type="bibr" rid="bib39">Moorlag et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Zervopoulou et al., 2024</xref>) as well as an anti-cancer treatment (<xref ref-type="bibr" rid="bib64">Vuscan et al., 2024</xref>; <xref ref-type="bibr" rid="bib24">Kalafati et al., 2020</xref>). While we and others have shown that β-glucan can induce central trained immunity by functionally reprogramming the HSC compartment in the bone marrow, the present study highlights an additional facet of β-glucan’s immunomodulatory effects on residential immune cells. Here we show that a single intraperitoneal (i.p.) injection of β-glucan can induce trained immunity in the lung AMs and functionally reprograms AMs at both the transcriptional and metabolic levels. These findings underscore the occurrence of tissue-specific immune training following systemic treatment, demonstrating processes of β-glucan-mediated peripheral trained immunity occurring in parallel with central immunity. We subsequently demonstrate that β-glucan-trained AMs can be detrimental after LPS or poly(I:C) administration causing severe ALI. Thus, this study is shedding light on the deleterious effects of trained immunity and its impact on immunopathology, which is incompletely understood.</p><p>There are several key features in trained immunity, including shifts in epigenetic and transcriptomic profiles after initial stimulation that returns to steady states. However, this epigenetic and metabolic remodelling result in long-term memory with heightened responses to diverse secondary stimulation (<xref ref-type="bibr" rid="bib10">Divangahi et al., 2021</xref>). The nature of each stimulus appears to be critical in determining the immunological outcome. While we show here that β-glucan aggravates LPS-induced immunopathology, repeated challenges of LPS has also long been associated with a dampening of immune responses, termed tolerance (<xref ref-type="bibr" rid="bib14">Freudenberg and Galanos, 1988</xref>; <xref ref-type="bibr" rid="bib35">Mason et al., 1997</xref>). However, ambient exposure of LPS has also been linked with training leading to enhanced bacterial clearance (<xref ref-type="bibr" rid="bib74">Zahalka et al., 2022</xref>). Evidently, the impacts of trained immunity are intricate and context dependent. We postulate two signals are required for the induction of trained immunity: signal 1, which is essential for reprogramming innate immune cells centrally (HSCs) or peripherally (e.g., AMs), and signal 2, an environmental cue critical for activating their functional capacity. In this study, we provide evidence supporting this conceptual framework.</p><p>β-Glucan-trained AMs were able to generate a robust response both in vitro and in vivo to bacterial (LPS) or viral (poly(I:C)) ligands. The increased response in β-glucan-trained AM was maintained up to 28 days, which is an indication of long-term reprogramming of AMs. The reprogramming of trained AMs was supported by significant alterations in both the transcriptomic and metabolic states. Using adoptive transfer experiments, we then showed that the functional reprogramming of β-glucan-trained AMs persisted even in the absence of the initial systemic β-glucan administration. This finding highlights the persistence of the intrinsic training program in AMs.</p><p>AMs are originated from yolk sac and fetal liver monocytes, which seeds the lung as soon as we take our first breath of air (<xref ref-type="bibr" rid="bib17">Guilliams et al., 2013</xref>). Importantly, AMs are the first immune cell to response to any particles or pathogens that reach the lower airways of the lungs, thus alterations in their functional capacity can significantly impact subsequent immune responses. For instance, given AMs are in direct contact with surfactant (produced by alveolar type 2 epithelial cells) and invading pathogens, a defect in GM-CSF or TGFβ signalling leads to accumulation of surfactant (alveolar proteinosis) and increased susceptibility to pulmonary infections (<xref ref-type="bibr" rid="bib4">Baker et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Huffman et al., 1996</xref>). AMs are able to sense and integrate multiple environmental signals – such as pH (<xref ref-type="bibr" rid="bib21">Huffman et al., 1996</xref>), temperature (<xref ref-type="bibr" rid="bib25">Kashio et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Link et al., 2010</xref>), osmolarity (<xref ref-type="bibr" rid="bib12">Fang et al., 2009</xref>), metabolites including fatty acids (<xref ref-type="bibr" rid="bib19">Haldar et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Okabe and Medzhitov, 2014</xref>), extracellular membrane components, and danger signals (<xref ref-type="bibr" rid="bib57">Sun et al., 2013</xref>) – to maintain tissue homeostasis (<xref ref-type="bibr" rid="bib45">Okabe and Medzhitov, 2016</xref>). However, the mechanisms underlying their ability to adapt to environmental stimuli while maintaining lung tissue homeostasis without impairing gas exchange is largely unknown (<xref ref-type="bibr" rid="bib29">Lazarov et al., 2023</xref>). AMs exhibit a remarkable plasticity, demonstrating a spectrum of functional polarization that ranges from regulatory to pro- and anti-inflammatory states. For instance, AM anti-inflammatory polarization in a LPS model of sepsis was TNF dependent, as AMs exposed to TNF exhibited diminished phagocytosis, superoxide anion (O<sub>2</sub><sup>−</sup>) and CXCL1 production, with reduced neutrophils recruitment (<xref ref-type="bibr" rid="bib35">Mason et al., 1997</xref>). Consequently, these mice had a reduction in lung clearance of <italic>P. aeruginosa</italic> infection. Influenza virus was able to induce similar anti-inflammatory function in AMs with decreased CXCL1 production and neutrophils recruitment via type I IFN pathway (<xref ref-type="bibr" rid="bib56">Shirey et al., 2019</xref>), leading to an increased susceptibility to super bacterial infection. On the other hand, AMs appear to be more resistant to polarization towards a pro-inflammatory state (<xref ref-type="bibr" rid="bib62">Tomlinson et al., 2012</xref>). A recent study demonstrated that exposure of lungs to ambient amount of LPS trains AMs in type I IFN dependent, but type II IFN and T cell-independent manner (<xref ref-type="bibr" rid="bib74">Zahalka et al., 2022</xref>). However, in our model system, systemic administration of β-glucan trains AMs in a type II IFN dependent, but type I IFN-independent manner. Similarly, in live infection models, we and others have identified IFNγ signalling a key player in AM training after BCG vaccination (<xref ref-type="bibr" rid="bib63">Tran et al., 2024</xref>), influenza infection (<xref ref-type="bibr" rid="bib65">Wang et al., 2023</xref>), pneumococcal infection (<xref ref-type="bibr" rid="bib2">Arafa et al., 2022</xref>), and intranasal infection with an adenoviral vector (<xref ref-type="bibr" rid="bib76">Zhou and Liao, 2021</xref>). Although we have not identified which cells produce IFNγ in the β-glucan model, it has been demonstrated by our group and others that following BCG vaccination, CD4+ T cells are the major source of IFNγ (<xref ref-type="bibr" rid="bib63">Tran et al., 2024</xref>), whereas after pulmonary adenovirus infection, CD8+ T cells predominantly produce IFNγ (<xref ref-type="bibr" rid="bib73">Yao et al., 2018</xref>). Influenza infection has also been described to induce IFNγ-dependent AM training with NK cells being the major source (<xref ref-type="bibr" rid="bib65">Wang et al., 2023</xref>). Interestingly, we found that neutrophils were also required for β-glucan-mediated AMs training. We have recently shown that β-glucan can reprogram HSCs via Dectin 1 and type I IFN signalling to promote granulopoiesis and the generation of trained neutrophils promoting disease tolerance to influenza infection (<xref ref-type="bibr" rid="bib27">Khan et al., 2025</xref>). Although we have shown that the recruitment of these trained neutrophils and type II IFN signalling were required for training AMs, the cellular and molecular mechanisms involved in this dialogue is unknown and requires further investigation. Interestingly, we have recently demonstrated that, in addition to GM-CSF and TGFβ signalling, neutrophils are critical for AMs self-renewal and maintenance during early lung development via the production of 12-hydroxyeicosatetraenoic acid (12-HETE) (<xref ref-type="bibr" rid="bib48">Pernet et al., 2023</xref>). The absence of 12-HETE leads to a significant reduction in the number AMs in adult lungs, enhanced senescence, and consequently increased susceptibility to IAV or SARS-CoV-2 infection. Thus, there might be a constant bidirectional dialogue between neutrophils and AMs, with neutrophils providing cues from internal organelles to AMs, and AMs offering signals from the external environment to neutrophils, which then return to their graveyard in the BM.</p><p>Although we have not directly tested the contribution of circulating monocytes in the initial reprogramming of AMs via β-glucan, the persistence of trained immunity by adoptively transferred AMs into <italic>Csf2rb<sup>−/−</sup></italic> mice suggests that the maintenance of the trained AM state was independent of bone marrow-derived monocytes. Additionally, the findings from Theobald et al. indicate that Dectin-1 is the receptor responsible for recognizing β-glucan which has been shown to activate macrophages and induce trained immunity in several models (<xref ref-type="bibr" rid="bib27">Khan et al., 2025</xref>; <xref ref-type="bibr" rid="bib9">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Arts et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Quintin et al., 2012</xref>). Here we found that β-glucan-mediated AM training, when administered systemically, was independent of Dectin-1. There are two potential explanations for this observation. First, it has been shown that β-glucan can also activate signalling via other TLRs, particularly TLR2 or complement receptor 3 (CR3) (<xref ref-type="bibr" rid="bib71">Yadav and Schorey, 2006</xref>; <xref ref-type="bibr" rid="bib61">Thornton et al., 1996</xref>; <xref ref-type="bibr" rid="bib68">Xia et al., 1999</xref>), and second as the β-glucan is a particulate, its internalization by phagocytes can also initiate signalling (<xref ref-type="bibr" rid="bib36">McLeish et al., 1998</xref>; <xref ref-type="bibr" rid="bib72">Yang et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Qi et al., 2011</xref>). Additionally, our understanding of how administration of β-glucan in peritoneal cavity leads to HSCs training in the BM and AMs training in thoracic cavity is extremely limited. Thus, addressing the molecular mechanisms of β-glucan signalling pathways (e.g., Dectin1 dependent and independent) in both immune and non-immune cells, as well as its mode of action (e.g., direct access to an organ versus indirect effects via systemic release of cytokines), is necessary to delineate the deleterious versus protective effects of β-glucan-mediated trained immunity.</p><p>β-Glucan is present in the cell wall of all fungi but will vary between different species and strains. In fact, the differential 1,3-1,6 glycosidic branching and molecular weight significantly impacts the response to the compound with a large variability of scientific findings contingent on the type of β-glucan used in a study (<xref ref-type="bibr" rid="bib34">Luo et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Moerings et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Akramiene et al., 2007</xref>). Fungi make up a portion of the human microbiome, termed the mycobiome. Several studies have described a high mycotic diversity between different populations, and even significant variability within an individual overtime (<xref ref-type="bibr" rid="bib58">Sun et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Szóstak et al., 2023</xref>; <xref ref-type="bibr" rid="bib40">Nash et al., 2017</xref>). The variance in gut colonization by fungal species can moreover cause gut dysbiosis which has been associated with poorer outcomes during SARS-CoV-2 infection, sepsis and cancer immunotherapy (<xref ref-type="bibr" rid="bib52">Reinold et al., 2022</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Huang et al., 2023</xref>; <xref ref-type="bibr" rid="bib47">Orieux et al., 2023</xref>; <xref ref-type="bibr" rid="bib49">Prevel et al., 2022</xref>). It is tempting to postulate that the levels of the mycobiome as well as its composition can influence subsequent immune reactions partly due to a distinct β-glucan makeup. In fact, antibodies to various types of β-glucan was detected in adult sera with different levels correlating with a person’s occupation (<xref ref-type="bibr" rid="bib43">Noss et al., 2012</xref>). Thus, the quantity and quality of circulating β-glucan in an individual at steady state can remarkably affect the subsequent immune responses to sterile or microbial inflammation. The concept of detrimental training by endogenous agents has also been described with heme, which similarly aggravated LPS-induced inflammation (<xref ref-type="bibr" rid="bib23">Jentho et al., 2021</xref>.) Basal levels of such immunomodulatory molecules provide a basis for host response heterogeneity and corresponding excessive inflammation (<xref ref-type="bibr" rid="bib16">Grasselli et al., 2020</xref>). Understanding these underlying processes may provide important insights for developing novel therapeutic approaches against immune-mediated pulmonary disease.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6</td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom">Strain #: 000664; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Csf2rb<sup>−/−</sup></italic></td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom">Strain #: 005940; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:005940">IMSR_JAX:005940</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Clec7a (Dectin1)<sup>−/−</sup></italic></td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom">Strain #: 012337; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:012337">IMSR_JAX:012337</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Ifnar<sup>−/−</sup></italic></td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom">Strain #: 028288; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:028288">IMSR_JAX:028288</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>IfngR<sup>−/−</sup></italic></td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom">Strain #: 003288; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:003288">IMSR_JAX:003288</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse CXCL1 DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: DY453</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse TNF-alpha DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: DY410</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IL-6 DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: DY406</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IFNγ DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: DY485</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA assay</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat #: 23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Seahorse XF Cell Mito Stress Test Kit</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat #: 103015-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Fixable Viability Dye eFluor 506</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat #: 65-0866-14</td><td align="left" valign="bottom">FACS (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 553141; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_394656">AB_394656</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-Cy7-conjugated anti-CD11c (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 561022; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_647251">AB_647251</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV786-conjugated anti-Siglec-F (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 740956; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2740581">AB_2740581</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BUV395-conjugated anti-CD11b (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 565976; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2738276">AB_2738276</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC-Cy7-conjugated anti-Ly6G (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 560600; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1727561">AB_1727561</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BUV737-conjugated anti-CD45.2 (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 612778; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2870107">AB_2870107</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE-conjugated anti-IFNγ (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 554412; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_395376">AB_395376</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC-conjugated anti-CD45.2 (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 553772; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_395041">AB_395041</ext-link></td><td align="left" valign="bottom">In vivo (2 µg per mouse)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BUV395-conjugated anti-CD45.2 (Mouse monoclonal)</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat #: 564616; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2738867">AB_2738867</ext-link></td><td align="left" valign="bottom">FACS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Depleting anti-IFNγ (rat IgG1k) (Mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat #: 505801; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_315395">AB_315395</ext-link></td><td align="left" valign="bottom">In vivo (200 µg per mouse)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Depleting anti-Ly6G (rat IgG2a,k) (Mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat #: 127601; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1089179">AB_1089179</ext-link></td><td align="left" valign="bottom">In vivo (70 µl per mouse)</td></tr><tr><td align="left" valign="bottom">Chemical compound</td><td align="left" valign="bottom">Clodronate liposomes</td><td align="left" valign="bottom">Liposoma BV</td><td align="left" valign="bottom">Cat #: C-005</td><td align="left" valign="bottom">In vivo (200 µg per mouse)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom"><italic>Escherichia coli</italic> O55:B55 LPS</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat #: L2637</td><td align="left" valign="bottom">In vivo (50 µg per mouse)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">β-1,3-Glucan purified from <italic>Saccharomyces cerevisiae</italic></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat #: G5011</td><td align="left" valign="bottom">In vivo (1 mg per mouse)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Poly(I:C) HMW</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Cat #: tlrl-pic</td><td align="left" valign="bottom">In vivo (50 µg per mouse)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6, <italic>Csf2rb<sup>−/−</sup></italic>, <italic>Clec7a<sup>−/−</sup></italic>, <italic>Ifnar<sup>−/−</sup></italic>, and <italic>IfngR<sup>−/−</sup></italic> mice were purchased from Jackson Laboratories. All animals were housed and inbred at the animal facility of the Research Institute of McGill University under specific pathogen-free conditions with ad libitum access to food and water, a temperature of 21°C (±1°C), relative humidity of 40–60% (±5%), and light cycle of 12 hr on, 12 hoff (daily cycle). <italic>Sex as a biological variable</italic>: Mice were randomly allocated to experimental groups, and experiments were performed using both female and male age- and sex-matched mice. Similar findings were reported for both sexes.</p></sec><sec id="s4-2"><title>β-Glucan training</title><p>Mice were administered intraperitoneally with 1 mg of β-1,3-glucan purified from <italic>Saccharomyces cerevisiae</italic> (Sigma) diluted in 100 µl of PBS 7 or 28 days before lung injury or AMs collection for ex vivo stimulation.</p></sec><sec id="s4-3"><title>ALI models</title><p>Mice were administered with 50 µg of <italic>Escherichia coli</italic> O55:B55 LPS (Sigma) or poly(I:C) (Invivogen) in PBS (25 µl per mouse, intranasally) to induce TLR-4- or 3-mediated ALI, respectively.</p></sec><sec id="s4-4"><title>Lung microCT scan</title><p>The trachea was cannulated with a 22-gauge cannula and an intra-thoracic pressure of 25 mmH<sub>2</sub>O was generated using a manometer. Images were acquired right after lung inflation using the nanoScan SPECT + CT (Mediso) allowing a resolution of 20 µm. DICOM software was used to analyse the microCT scans determining the average lung Hounsfield unit (HU) and the proportion of non- or poorly aerated lung (HU –500; +100).</p></sec><sec id="s4-5"><title>BAL and lung collection</title><p>Broncho-alveolar lavage (BAL) samples collected by cannulating the trachea with a 22-gauge cannula, then washing the lungs with 3× 1 ml of cold, sterile PBS. The total volume of the recovered fluid after lavage was around 0.7 ml. Samples were centrifuged (1500 rpm, 10 min). Lung tissues were perfused with 10 ml of PBS, collected and minced before collagenase type I (3 mg, Worthington CLS-1), elastase (3 mg, Worthington ESL), and DNase I (0.4 mg, Worthington D) digestion for 30 min at 37°C. Lungs were filtered through a 70-µm nylon mesh, and red blood cells were lysed.</p></sec><sec id="s4-6"><title>Endothelial permeability</title><p>LPS or poly(I:C)-challenged mice were intravenously injected with 400 µl of Evan’s blue dye (2% in PBS) into the mice. After 1 hr, mice were euthanized, and lungs were perfused with 10 ml of PBS. Evan’s blue then extracted by overnight incubation in formamide at 56°C (lungs) and quantified by spectrophotometry analysis using a standard curve of Evan’s blue in formamide.</p></sec><sec id="s4-7"><title>Histopathological analysis</title><p>Histopathological analysis was performed as previously described (<xref ref-type="bibr" rid="bib48">Pernet et al., 2023</xref>). Lungs were inflated and fixed for 48 hr with 10% formalin, and then embedded in paraffin. Sections (5 µm) were cut and stained with haematoxylin and eosin. Slides were scanned at a resolution of ×40 magnification, and pictures were taken using a Leica Aperio slide scanner (Leica). Histology samples were evaluated according to ATS 2011 guidelines regarding ‘Features and measurements of experimental ALI in animals’ by a blinded observer.</p></sec><sec id="s4-8"><title>ELISA</title><p>CXCL1, TNF-α, IL-6, and IFNγ levels in BAL were assessed by ELISA (R&amp;D Systems).</p></sec><sec id="s4-9"><title>Protein in BAL</title><p>Samples were centrifuged (1500 rpm, 10 min), and total protein content was assessed using a Pierce BCA Protein assay (Thermo Fisher).</p></sec><sec id="s4-10"><title>Flow cytometry</title><p>BAL and total lung cell counts were determined with a haemocytometer, and 1–2 illion cells were used for staining. Cells were initially stained with viability dye e506 (Invitrogen, 20 min, 4°C) and surface stained with anti-CD16/32 (BD Bioscience) in 0.5% BSA/PBS solution to block nonspecific AB interaction with Fc receptors (10 min, 4°C). Cells were then surface-stained with different combinations of PE-Cy7-conjugated anti-CD11c, BUV786-conjugated anti-Siglec-F, BUV395-conjugated anti-CD11b, APC-Cy7-conjugated anti-Ly6G, and BUV737-conjugated anti-CD45.2 antibodies (all from BD Biosciences). For IFNγ intra-cellular staining, cells were fixed and permeabilized using BD CytoFix/CytoPerm (BD Bioscience) before intracellular staining with PE-conjugated anti-IFNγ antibodies (BD Biosciences). Flow cytometry was performed using a BD LSR Fortessa X-20 instrument (BD Biosciences) with FACSDiva software v.8.0.1 (BD Biosciences). Analysis was performed using FlowJo software v.10.7.1 (Tree Star).</p></sec><sec id="s4-11"><title>Intravascular staining</title><p>In vivo discrimination between pulmonary vasculature and parenchyma was performed as previously described (<xref ref-type="bibr" rid="bib48">Pernet et al., 2023</xref>). Adult WT mice were given 2 µg of FITC-conjugated anti-CD45.2 intravenously to label all circulating cells. Three minutes later, mice were euthanized and lungs collected, stained ex vivo with BUV395-conjugated anti-CD45.2 antibody to determine the parenchymal (cells only labelled with the ex vivo antibody) or vascular localization of the cells (cells labelled with both antibodies).</p></sec><sec id="s4-12"><title>AM depletion</title><p>WT mice were treated with control or clodronate liposomes (70 µl, intranasally; Liposoma BV). The LPS-induced ALI was then performed at day 2 after clodronate instillation.</p></sec><sec id="s4-13"><title>Adoptive transfer models</title><p>AMs from WT mice which received i.p. PBS or β-glucan were collected as described above and resuspended at a density of 5 × 10<sup>4</sup> cells per 5–7 µl of RPMI1640 medium supplemented with 10% (vol/vol) FBS, 2 mM <sc>L</sc>-glutamine, 10 mM HEPES, and 100 U ml<sup>–1</sup> penicillin–streptomycin. AMs were then transferred by the intranasal route into day 2 <italic>Csf2rb<sup>−/−</sup></italic> pups. LPS-induced ALI was performed 6 weeks after AM adoptive transfer. BAL and lung tissue were collected and processed as described above for endothelial permeability, flow cytometry, total BAL cytokine, and protein content experiments.</p></sec><sec id="s4-14"><title>Isolation and culture of AMs</title><p>AMs were collected by BAL of naive mice using cold, sterile PBS (5 × 1 ml for adult mice). AMs were cultured in the specific media described above. After 1 hr of adhesion, AMs were washed with PBS and placed in fresh medium.</p></sec><sec id="s4-15"><title>Ex vivo stimulation</title><p>AMs from WT, <italic>Dectin1<sup>−/−</sup></italic>, <italic>Ifnar<sup>−/</sup></italic><sup>−</sup>, and <italic>IfngR<sup>−/−</sup></italic> mice which received i.p. PBS or β-glucan were collected as described above and 5 × 10<sup>4</sup> cells in specific media were distributed per well. AMs were stimulated with 50 ng/ml of LPS (Sigma) for 4 hr at 37°C.</p></sec><sec id="s4-16"><title>Library preparation and RNA-seq</title><p>Total RNA was collected from BAL AMs from four WT mice per conditions (i.p PBS, no ex vivo stimulation/i.p. β-glucan, no ex vivo stimulation/i.p PBS, ex vivo LPS stimulation/i.p. β-glucan, ex vivo LPS stimulation). After RNA quality controls, sequencing libraries were constructed using the Illumina TruSeq protocol. Libraries were sequenced on an Illumina NovaSeq 6000 (paired-end 100 base pair) to an average depth of 51,189,336 reads per sample.</p></sec><sec id="s4-17"><title>RNA-seq data analysis</title><p>RNA-seq reads were aligned to the <italic>Mus musculus</italic> genome from Ensembl version 99 using STAR (version 2.7.3a) was used (<xref ref-type="bibr" rid="bib11">Dobin et al., 2013</xref>). All regions overlapped between referenced exons and alignments were counted using featureCounts (subread-1.6.4) (<xref ref-type="bibr" rid="bib31">Liao et al., 2014</xref>). Low abundance genes were filtered out leaving 12,894 genes for subsequent analysis.</p><p>Differential expression analyses were performed using the DESeq2 package (DESeq2 1.40.2) (<xref ref-type="bibr" rid="bib33">Love et al., 2014</xref>). Gene ontology analysis was realized with the R package TopGO. For GSEA a ranked list of the differentially expressed genes was used with clusterProfiler v4.8.2 (<xref ref-type="bibr" rid="bib67">Wu et al., 2021</xref>), and the Molecular Signatures Database MSigDB v7.5.1.</p></sec><sec id="s4-18"><title>Extracellular flux analysis</title><p>Seahorse assay of isolated cells was performed as previously described (<xref ref-type="bibr" rid="bib48">Pernet et al., 2023</xref>). Real-time OCRs of AMs were measured in XF medium (non-buffered RPMI containing 2 mM <sc>L</sc>-glutamine, 25 mM glucose, and 1 mM sodium pyruvate) using a Seahorse Xfe 96 Analyzer (Agilent Technologies). For the mitochondrial stress test, mitochondrial inhibitors oligomycin (1.5 µM), fluorocarbonyl cyanide phenylhydrazone (FCCP) (1 µM), antimycin A, and rotenone (0.5 µM) were used as per the manufacturer’s recommendations. In brief, cells were seeded at a density of 100,000 cells per well and 3 basal measurements were taken. Following this, two consecutive measurements were taken following each injection of oligomycin, FCCP, and antimycin A with rotenone. All measurements were normalized to cell number using crystal violet dye extraction assay. Oxygen consumption curves, OCRs and ECARs were generated using Wave Desktop 2.3 (Agilent Technologies).</p></sec><sec id="s4-19"><title>IFNγ and neutrophils depletion experiments</title><p>Sex- and age-matched adult WT mice received intra-peritoneal 200 µg of anti-IFNγ (rat IgG1k, Biolegend), anti-Ly6G (rat IgG2a,k, Biolegend) or appropriated control isotypes injection at days 1, 0, 2, 4, and 6 per intraperitoneal injection of β-glucan. AMs collection for ex vivo stimulation was performed at day 7 after intraperitoneal β-glucan injection.</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>No statistical methods were used to pre-determine samples sizes. Sample sizes were empirically determined to optimize numbers based on previous experience with equivalent experiments reported in previous publications (<xref ref-type="bibr" rid="bib63">Tran et al., 2024</xref>; <xref ref-type="bibr" rid="bib48">Pernet et al., 2023</xref>). A minimum sample size of 3 was always included for statistical analysis to be valid. Data distribution was assumed to be normal, but this was not formally tested. No data points were excluded from analysis. Key experiments were reproduced independently two times for reproducibility of findings except RNA-seq as we considered the high output of data to be sufficient to corroborate our other reproducible findings. Experimentally intricate experiments such as Ly6G/IFNγ depletion and neonatal adoptive transfer was performed once. All experiments involve mice or mouse-derived samples. Mice of the same sex were age-matched and randomly assigned prior to the initiation of experiments. Data collection and analysis were not performed blinded to the experimental conditions as experiments were all done by one researcher at a time. Statistical analyses were performed using GraphPad Prism v.9.1.2 software (GraphPad). Statistical differences were determined using one-way ANOVA followed by Dunn’s multiple comparisons test, paired or unpaired two-tailed <italic>t</italic>-test or two-tailed Mann–Whitney test. Differential gene expression analysis was carried out using DEseq2 package (<xref ref-type="bibr" rid="bib33">Love et al., 2014</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Data curation</p></fn><fn fn-type="con" id="con7"><p>Data curation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experiments involving animals were approved by the McGill University Animal Care Committee (permit number 2010-5860) in accordance with the guidelines set out by the Canadian Council on Animal Care.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102068-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data supporting the findings of this study are included in the published article and supplementary materials. Bulk RNA-seq data have been deposited to the European Nucleotide Archive and can accessed on <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/browser/home">https://www.ebi.ac.uk/ena/browser/home</ext-link> with accession code PRJEB75517 and secondary accession code ERP160094. Source data are provided with this paper.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Prével</surname><given-names>R</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>KA</given-names></name><name><surname>Sadek</surname><given-names>A</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Lapshina</surname><given-names>E</given-names></name><name><surname>Jurado</surname><given-names>L</given-names></name><name><surname>Kristof</surname><given-names>AS</given-names></name><name><surname>Moumni</surname><given-names>M</given-names></name><name><surname>Poschmann</surname><given-names>J</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>β-glucan enhances LPS-induced acute lung injury via interferon γ-mediated alveolar macrophages reprogramming</data-title><source>EBI European Nucleotide Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB75517">PRJEB75517</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors acknowledge technical help from staff at the RI-MUHC histopathology platform and RI-MUHC Small Animal Imaging Laboratory. M.D. is funded by Canadian Institute of Health Research (CIHR) Project Grant-168885 and MM1174910, a Fonds de recherche du Québec Santé (FRQS) Award, holds the Strauss Chair in Respiratory Diseases and is a fellow member of the Royal Society of Canada. E.P. and R.P. are fellows supported by a Postdoctoral Fellowship from the Fonds de Recherche du Québec Santé.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akramiene</surname><given-names>D</given-names></name><name><surname>Kondrotas</surname><given-names>A</given-names></name><name><surname>Didziapetriene</surname><given-names>J</given-names></name><name><surname>Kevelaitis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effects of beta-glucans on the immune system</article-title><source>Medicina</source><volume>43</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">17895634</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arafa</surname><given-names>EI</given-names></name><name><surname>Shenoy</surname><given-names>AT</given-names></name><name><surname>Barker</surname><given-names>KA</given-names></name><name><surname>Etesami</surname><given-names>NS</given-names></name><name><surname>Martin</surname><given-names>IM</given-names></name><name><surname>Lyon De Ana</surname><given-names>C</given-names></name><name><surname>Na</surname><given-names>E</given-names></name><name><surname>Odom</surname><given-names>CV</given-names></name><name><surname>Goltry</surname><given-names>WN</given-names></name><name><surname>Korkmaz</surname><given-names>FT</given-names></name><name><surname>Wooten</surname><given-names>AK</given-names></name><name><surname>Belkina</surname><given-names>AC</given-names></name><name><surname>Guillon</surname><given-names>A</given-names></name><name><surname>Forsberg</surname><given-names>EC</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Mizgerd</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Recruitment and training of alveolar macrophages after pneumococcal pneumonia</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e150239</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.150239</pub-id><pub-id pub-id-type="pmid">35133985</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Lachmandas</surname><given-names>E</given-names></name><name><surname>Rodrigues</surname><given-names>F</given-names></name><name><surname>Silvestre</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Wang</surname><given-names>S-Y</given-names></name><name><surname>Habibi</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>LG</given-names></name><name><surname>Mesquita</surname><given-names>I</given-names></name><name><surname>Cunha</surname><given-names>C</given-names></name><name><surname>van Laarhoven</surname><given-names>A</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Clish</surname><given-names>C</given-names></name><name><surname>Notebaart</surname><given-names>RA</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>807</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.10.008</pub-id><pub-id pub-id-type="pmid">27866838</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>AD</given-names></name><name><surname>Malur</surname><given-names>A</given-names></name><name><surname>Barna</surname><given-names>BP</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Kavuru</surname><given-names>MS</given-names></name><name><surname>Malur</surname><given-names>AG</given-names></name><name><surname>Thomassen</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism</article-title><source>Journal of Lipid Research</source><volume>51</volume><fpage>1325</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1194/jlr.M001651</pub-id><pub-id pub-id-type="pmid">20064973</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broquet</surname><given-names>A</given-names></name><name><surname>Gourain</surname><given-names>V</given-names></name><name><surname>Goronflot</surname><given-names>T</given-names></name><name><surname>Le Mabecque</surname><given-names>V</given-names></name><name><surname>Sinha</surname><given-names>D</given-names></name><name><surname>Ashayeripanah</surname><given-names>M</given-names></name><name><surname>Jacqueline</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Davieau</surname><given-names>M</given-names></name><name><surname>Boutin</surname><given-names>L</given-names></name><name><surname>Poulain</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>FP</given-names></name><name><surname>Fourgeux</surname><given-names>C</given-names></name><name><surname>Petrier</surname><given-names>M</given-names></name><name><surname>Cannevet</surname><given-names>M</given-names></name><name><surname>Leclercq</surname><given-names>T</given-names></name><name><surname>Guillonneau</surname><given-names>M</given-names></name><name><surname>Chaumette</surname><given-names>T</given-names></name><name><surname>Laurent</surname><given-names>T</given-names></name><name><surname>Harly</surname><given-names>C</given-names></name><name><surname>Scotet</surname><given-names>E</given-names></name><name><surname>Legentil</surname><given-names>L</given-names></name><name><surname>Ferrières</surname><given-names>V</given-names></name><name><surname>Corgnac</surname><given-names>S</given-names></name><name><surname>Mami-Chouaib</surname><given-names>F</given-names></name><name><surname>Mosnier</surname><given-names>JF</given-names></name><name><surname>Mauduit</surname><given-names>N</given-names></name><name><surname>McWilliam</surname><given-names>HEG</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name><name><surname>Gourraud</surname><given-names>PA</given-names></name><name><surname>Asehnoune</surname><given-names>K</given-names></name><name><surname>Poschmann</surname><given-names>J</given-names></name><name><surname>Roquilly</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Sepsis-trained macrophages promote antitumoral tissue-resident T cells</article-title><source>Nature Immunology</source><volume>25</volume><fpage>802</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-01819-8</pub-id><pub-id pub-id-type="pmid">38684922</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burastero</surname><given-names>SE</given-names></name><name><surname>Magnani</surname><given-names>Z</given-names></name><name><surname>Confetti</surname><given-names>C</given-names></name><name><surname>Abbruzzese</surname><given-names>L</given-names></name><name><surname>Oddera</surname><given-names>S</given-names></name><name><surname>Balbo</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>GA</given-names></name><name><surname>Crimi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation to autologous TH2 lymphocytes</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>103</volume><fpage>1136</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/s0091-6749(99)70189-2</pub-id><pub-id pub-id-type="pmid">10359896</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilli</surname><given-names>G</given-names></name><name><surname>Tabouret</surname><given-names>G</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The complexity of fungal β-glucan in health and disease: effects on the mononuclear phagocyte system</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>673</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00673</pub-id><pub-id pub-id-type="pmid">29755450</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>BC</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>KX</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Association between gut dysbiosis and sepsis-induced myocardial dysfunction in patients with sepsis or septic shock</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>12</volume><elocation-id>857035</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.857035</pub-id><pub-id pub-id-type="pmid">35372123</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>RA</given-names></name><name><surname>Shepardson</surname><given-names>KM</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Manjeri</surname><given-names>GR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van der Veer</surname><given-names>BMJW</given-names></name><name><surname>Deen</surname><given-names>PMT</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Willems</surname><given-names>P</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1250684</elocation-id><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>DiNardo</surname><given-names>AR</given-names></name><name><surname>Dominguez-Andres</surname><given-names>J</given-names></name><name><surname>Duivenvoorden</surname><given-names>R</given-names></name><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Fayad</surname><given-names>Z</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Mhlanga</surname><given-names>M</given-names></name><name><surname>Moorlag</surname><given-names>SJ</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>O’Neill</surname><given-names>L</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Sauerwein</surname><given-names>R</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Sieweke</surname><given-names>MH</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Stunnenberg</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Xavier</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Trained immunity, tolerance, priming and differentiation: distinct immunological processes</article-title><source>Nature Immunology</source><volume>22</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-00845-6</pub-id><pub-id pub-id-type="pmid">33293712</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>HY</given-names></name><name><surname>Hughes</surname><given-names>R</given-names></name><name><surname>Murdoch</surname><given-names>C</given-names></name><name><surname>Coffelt</surname><given-names>SB</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name><name><surname>Imityaz</surname><given-names>HZ</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><name><surname>Fredlund</surname><given-names>E</given-names></name><name><surname>Greten</surname><given-names>FR</given-names></name><name><surname>Rius</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia</article-title><source>Blood</source><volume>114</volume><fpage>844</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-195941</pub-id><pub-id pub-id-type="pmid">19454749</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>SL</given-names></name><name><surname>Hargreaves</surname><given-names>DC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Gene-specific control of inflammation by TLR-induced chromatin modifications</article-title><source>Nature</source><volume>447</volume><fpage>972</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1038/nature05836</pub-id><pub-id pub-id-type="pmid">17538624</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freudenberg</surname><given-names>MA</given-names></name><name><surname>Galanos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages</article-title><source>Infection and Immunity</source><volume>56</volume><fpage>1352</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1128/iai.56.5.1352-1357.1988</pub-id><pub-id pub-id-type="pmid">3356468</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>SE</given-names></name><name><surname>Rohan</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo</article-title><source>Respiratory Research</source><volume>16</volume><elocation-id>109</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-015-0266-7</pub-id><pub-id pub-id-type="pmid">26376777</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Tonetti</surname><given-names>T</given-names></name><name><surname>Protti</surname><given-names>A</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Girardis</surname><given-names>M</given-names></name><name><surname>Bellani</surname><given-names>G</given-names></name><name><surname>Laffey</surname><given-names>J</given-names></name><name><surname>Carrafiello</surname><given-names>G</given-names></name><name><surname>Carsana</surname><given-names>L</given-names></name><name><surname>Rizzuto</surname><given-names>C</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name><name><surname>Scaravilli</surname><given-names>V</given-names></name><name><surname>Pizzilli</surname><given-names>G</given-names></name><name><surname>Grieco</surname><given-names>DL</given-names></name><name><surname>Di Meglio</surname><given-names>L</given-names></name><name><surname>de Pascale</surname><given-names>G</given-names></name><name><surname>Lanza</surname><given-names>E</given-names></name><name><surname>Monteduro</surname><given-names>F</given-names></name><name><surname>Zompatori</surname><given-names>M</given-names></name><name><surname>Filippini</surname><given-names>C</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Fumagalli</surname><given-names>R</given-names></name><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>J-L</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Ranieri</surname><given-names>VM</given-names></name><collab>collaborators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>1201</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30370-2</pub-id><pub-id pub-id-type="pmid">32861276</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>De Kleer</surname><given-names>I</given-names></name><name><surname>Henri</surname><given-names>S</given-names></name><name><surname>Post</surname><given-names>S</given-names></name><name><surname>Vanhoutte</surname><given-names>L</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><name><surname>Deswarte</surname><given-names>K</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>1977</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1084/jem.20131199</pub-id><pub-id pub-id-type="pmid">24043763</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustine</surname><given-names>JN</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunopathology of hyperinflammation in COVID-19</article-title><source>The American Journal of Pathology</source><volume>191</volume><fpage>4</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.08.009</pub-id><pub-id pub-id-type="pmid">32919977</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haldar</surname><given-names>K</given-names></name><name><surname>George</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Mistry</surname><given-names>V</given-names></name><name><surname>Ramsheh</surname><given-names>MY</given-names></name><name><surname>Free</surname><given-names>RC</given-names></name><name><surname>John</surname><given-names>C</given-names></name><name><surname>Reeve</surname><given-names>NF</given-names></name><name><surname>Miller</surname><given-names>BE</given-names></name><name><surname>Tal-Singer</surname><given-names>R</given-names></name><name><surname>Webb</surname><given-names>AJ</given-names></name><name><surname>Brookes</surname><given-names>AJ</given-names></name><name><surname>Tobin</surname><given-names>MD</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Barer</surname><given-names>MR</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The sputum microbiome is distinct between COPD and health, independent of smoking history</article-title><source>Respiratory Research</source><volume>21</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-020-01448-3</pub-id><pub-id pub-id-type="pmid">32664956</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Xuan</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Tong</surname><given-names>T</given-names></name><name><surname>Ning</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts</article-title><source>Cell Host &amp; Microbe</source><volume>31</volume><fpage>1930</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.10.005</pub-id><pub-id pub-id-type="pmid">37944495</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huffman</surname><given-names>JA</given-names></name><name><surname>Hull</surname><given-names>WM</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name><name><surname>Mulligan</surname><given-names>RC</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice</article-title><source>The Journal of Clinical Investigation</source><volume>97</volume><fpage>649</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1172/JCI118461</pub-id><pub-id pub-id-type="pmid">8609219</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussell</surname><given-names>T</given-names></name><name><surname>Bell</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alveolar macrophages: plasticity in a tissue-specific context</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nri3600</pub-id><pub-id pub-id-type="pmid">24445666</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jentho</surname><given-names>E</given-names></name><name><surname>Ruiz-Moreno</surname><given-names>C</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Megchelenbrink</surname><given-names>WL</given-names></name><name><surname>Martins</surname><given-names>R</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Soares</surname><given-names>MP</given-names></name><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Guerra</surname><given-names>J</given-names></name><name><surname>Roestel</surname><given-names>F</given-names></name><name><surname>Bohm</surname><given-names>P</given-names></name><name><surname>Godmann</surname><given-names>M</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Eugster</surname><given-names>A</given-names></name><name><surname>Beretta</surname><given-names>M</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Trained innate immunity, long-lasting epigenetic modulation, and skewed myelopoiesis by heme</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2102698118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2102698118</pub-id><pub-id pub-id-type="pmid">34663697</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hatzioannou</surname><given-names>A</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Hagag</surname><given-names>E</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Has</surname><given-names>C</given-names></name><name><surname>Dietz</surname><given-names>S</given-names></name><name><surname>de Jesus Domingues</surname><given-names>AM</given-names></name><name><surname>Nati</surname><given-names>M</given-names></name><name><surname>Sormendi</surname><given-names>S</given-names></name><name><surname>Neuwirth</surname><given-names>A</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Ziogas</surname><given-names>A</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Subramanian</surname><given-names>P</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>KJ</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate immune training of granulopoiesis promotes anti-tumor activity</article-title><source>Cell</source><volume>183</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.058</pub-id><pub-id pub-id-type="pmid">33125892</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashio</surname><given-names>M</given-names></name><name><surname>Sokabe</surname><given-names>T</given-names></name><name><surname>Shintaku</surname><given-names>K</given-names></name><name><surname>Uematsu</surname><given-names>T</given-names></name><name><surname>Fukuta</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Tominaga</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Redox signal-mediated sensitization of transient receptor potential melastatin 2 (TRPM2) to temperature affects macrophage functions</article-title><source>PNAS</source><volume>109</volume><fpage>6745</fpage><lpage>6750</lpage><pub-id pub-id-type="doi">10.1073/pnas.1114193109</pub-id><pub-id pub-id-type="pmid">22493272</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mendonça</surname><given-names>LE</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><name><surname>Tzelepis</surname><given-names>F</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Dumaine</surname><given-names>A</given-names></name><name><surname>Grenier</surname><given-names>J-C</given-names></name><name><surname>Mailhot-Léonard</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Belle</surname><given-names>J</given-names></name><name><surname>Besla</surname><given-names>R</given-names></name><name><surname>Mazer</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Nijnik</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><volume>172</volume><fpage>176</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Tran</surname><given-names>KA</given-names></name><name><surname>Chevre</surname><given-names>R</given-names></name><name><surname>Locher</surname><given-names>V</given-names></name><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Herrero-Cervera</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>A</given-names></name><name><surname>Saif</surname><given-names>A</given-names></name><name><surname>Downey</surname><given-names>J</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name><name><surname>Joubert</surname><given-names>P</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Yipp</surname><given-names>BG</given-names></name><name><surname>Soehnlein</surname><given-names>O</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus</article-title><source>Nature Immunology</source><volume>26</volume><fpage>174</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-02041-2</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1722</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01722</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarov</surname><given-names>T</given-names></name><name><surname>Juarez-Carreño</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Physiology and diseases of tissue-resident macrophages</article-title><source>Nature</source><volume>618</volume><fpage>698</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06002-x</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Piattini</surname><given-names>F</given-names></name><name><surname>Pohlmeier</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Rehrauer</surname><given-names>H</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabj5761</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abj5761</pub-id><pub-id pub-id-type="pmid">35776802</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>TM</given-names></name><name><surname>Park</surname><given-names>U</given-names></name><name><surname>Vonakis</surname><given-names>BM</given-names></name><name><surname>Raben</surname><given-names>DM</given-names></name><name><surname>Soloski</surname><given-names>MJ</given-names></name><name><surname>Caterina</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TRPV2 has a pivotal role in macrophage particle binding and phagocytosis</article-title><source>Nature Immunology</source><volume>11</volume><fpage>232</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/ni.1842</pub-id><pub-id pub-id-type="pmid">20118928</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Purified β-glucans of different molecular weights enhance growth performance of LPS-challenged piglets via improved gut barrier function and microbiota</article-title><source>Animals</source><volume>9</volume><elocation-id>602</elocation-id><pub-id pub-id-type="doi">10.3390/ani9090602</pub-id><pub-id pub-id-type="pmid">31450592</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>CM</given-names></name><name><surname>Dobard</surname><given-names>E</given-names></name><name><surname>Summer</surname><given-names>WR</given-names></name><name><surname>Nelson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms</article-title><source>The Journal of Infectious Diseases</source><volume>176</volume><fpage>1293</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1086/514125</pub-id><pub-id pub-id-type="pmid">9359731</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLeish</surname><given-names>KR</given-names></name><name><surname>Klein</surname><given-names>JB</given-names></name><name><surname>Coxon</surname><given-names>PY</given-names></name><name><surname>Head</surname><given-names>KZ</given-names></name><name><surname>Ward</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Bacterial phagocytosis activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in human neutrophils</article-title><source>Journal of Leukocyte Biology</source><volume>64</volume><fpage>835</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">9850168</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L</given-names></name><name><surname>Reyfman</surname><given-names>PA</given-names></name><name><surname>Cuda</surname><given-names>CM</given-names></name><name><surname>Walter</surname><given-names>JM</given-names></name><name><surname>McQuattie-Pimentel</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>C-I</given-names></name><name><surname>Anekalla</surname><given-names>KR</given-names></name><name><surname>Joshi</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>KJN</given-names></name><name><surname>Abdala-Valencia</surname><given-names>H</given-names></name><name><surname>Yacoub</surname><given-names>TJ</given-names></name><name><surname>Chi</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>S</given-names></name><name><surname>Gonzalez-Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Gates</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>AP</given-names></name><name><surname>Nicholson</surname><given-names>TT</given-names></name><name><surname>Homan</surname><given-names>PJ</given-names></name><name><surname>Soberanes</surname><given-names>S</given-names></name><name><surname>Dominguez</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>VK</given-names></name><name><surname>Saber</surname><given-names>R</given-names></name><name><surname>Shaffer</surname><given-names>A</given-names></name><name><surname>Hinchcliff</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>SA</given-names></name><name><surname>Bharat</surname><given-names>A</given-names></name><name><surname>Berdnikovs</surname><given-names>S</given-names></name><name><surname>Bhorade</surname><given-names>SM</given-names></name><name><surname>Bartom</surname><given-names>ET</given-names></name><name><surname>Morimoto</surname><given-names>RI</given-names></name><name><surname>Balch</surname><given-names>WE</given-names></name><name><surname>Sznajder</surname><given-names>JI</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Mutlu</surname><given-names>GM</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Gottardi</surname><given-names>CJ</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Ridge</surname><given-names>KM</given-names></name><name><surname>Bagheri</surname><given-names>N</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Budinger</surname><given-names>GRS</given-names></name><name><surname>Perlman</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span</article-title><source>Journal of Experimental Medicine</source><volume>214</volume><fpage>2387</fpage><lpage>2404</lpage><pub-id pub-id-type="doi">10.1084/jem.20162152</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moerings</surname><given-names>BGJ</given-names></name><name><surname>de Graaff</surname><given-names>P</given-names></name><name><surname>Furber</surname><given-names>M</given-names></name><name><surname>Witkamp</surname><given-names>RF</given-names></name><name><surname>Debets</surname><given-names>R</given-names></name><name><surname>Mes</surname><given-names>JJ</given-names></name><name><surname>van Bergenhenegouwen</surname><given-names>J</given-names></name><name><surname>Govers</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Continuous exposure to non-soluble β-glucans induces trained immunity in M-CSF-differentiated macrophages</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>672796</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.672796</pub-id><pub-id pub-id-type="pmid">34149707</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>β-Glucan induces protective trained immunity against <italic>Mycobacterium tuberculosis</italic> infection: A key role for IL-1</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107634</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107634</pub-id><pub-id pub-id-type="pmid">32433977</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>AK</given-names></name><name><surname>Auchtung</surname><given-names>TA</given-names></name><name><surname>Wong</surname><given-names>MC</given-names></name><name><surname>Smith</surname><given-names>DP</given-names></name><name><surname>Gesell</surname><given-names>JR</given-names></name><name><surname>Ross</surname><given-names>MC</given-names></name><name><surname>Stewart</surname><given-names>CJ</given-names></name><name><surname>Metcalf</surname><given-names>GA</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Ajami</surname><given-names>NJ</given-names></name><name><surname>Petrosino</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The gut mycobiome of the human microbiome project healthy cohort</article-title><source>Microbiome</source><volume>5</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-017-0373-4</pub-id><pub-id pub-id-type="pmid">29178920</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Mills</surname><given-names>KHG</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trained immunity: a program of innate immune memory in health and disease</article-title><source>Science</source><volume>352</volume><elocation-id>aaf1098</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaf1098</pub-id><pub-id pub-id-type="pmid">27102489</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Stabell Benn</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noss</surname><given-names>I</given-names></name><name><surname>Wouters</surname><given-names>IM</given-names></name><name><surname>Smit</surname><given-names>LAM</given-names></name><name><surname>Meijer</surname><given-names>E</given-names></name><name><surname>Pronk</surname><given-names>A</given-names></name><name><surname>Heederik</surname><given-names>DJJ</given-names></name><name><surname>Doekes</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IgG to various beta-glucans in a human adult population</article-title><source>International Archives of Allergy and Immunology</source><volume>157</volume><fpage>98</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1159/000324674</pub-id><pub-id pub-id-type="pmid">21912179</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>Y</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tissue-specific signals control reversible program of localization and functional polarization of macrophages</article-title><source>Cell</source><volume>157</volume><fpage>832</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.04.016</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>Y</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue biology perspective on macrophages</article-title><source>Nature Immunology</source><volume>17</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/ni.3320</pub-id><pub-id pub-id-type="pmid">26681457</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opal</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Endotoxins and other sepsis triggers</article-title><source>Contributions to Nephrology</source><volume>167</volume><fpage>14</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1159/000315915</pub-id><pub-id pub-id-type="pmid">20519895</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orieux</surname><given-names>A</given-names></name><name><surname>Enaud</surname><given-names>R</given-names></name><name><surname>Imbert</surname><given-names>S</given-names></name><name><surname>Boyer</surname><given-names>P</given-names></name><name><surname>Begot</surname><given-names>E</given-names></name><name><surname>Camino</surname><given-names>A</given-names></name><name><surname>Boyer</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Gruson</surname><given-names>D</given-names></name><name><surname>Delhaes</surname><given-names>L</given-names></name><name><surname>Prevel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The gut microbiota composition is linked to subsequent occurrence of ventilator-associated pneumonia in critically ill patients</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0064123</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.00641-23</pub-id><pub-id pub-id-type="pmid">37713505</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Sarden</surname><given-names>N</given-names></name><name><surname>Gona</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mawhinney</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>KA</given-names></name><name><surname>Chronopoulos</surname><given-names>J</given-names></name><name><surname>Amberkar</surname><given-names>D</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>A</given-names></name><name><surname>Wali</surname><given-names>S</given-names></name><name><surname>Prevel</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JG</given-names></name><name><surname>Thanabalasuriar</surname><given-names>A</given-names></name><name><surname>Yipp</surname><given-names>BG</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Neonatal imprinting of alveolar macrophages via neutrophil-derived 12-HETE</article-title><source>Nature</source><volume>614</volume><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05660-7</pub-id><pub-id pub-id-type="pmid">36599368</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prevel</surname><given-names>R</given-names></name><name><surname>Enaud</surname><given-names>R</given-names></name><name><surname>Orieux</surname><given-names>A</given-names></name><name><surname>Camino</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Boyer</surname><given-names>A</given-names></name><name><surname>Delhaes</surname><given-names>L</given-names></name><name><surname>Gruson</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Gut bacteriobiota and mycobiota are both associated with Day-28 mortality among critically ill patients</article-title><source>Critical Care</source><volume>26</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-022-03980-8</pub-id><pub-id pub-id-type="pmid">35418098</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Gunn</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Kloecker</surname><given-names>G</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name><name><surname>Vasilakos</surname><given-names>J</given-names></name><name><surname>Saijo</surname><given-names>S</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Yannelli</surname><given-names>JR</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans</article-title><source>Blood</source><volume>117</volume><fpage>6825</fpage><lpage>6836</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-02-339812</pub-id><pub-id pub-id-type="pmid">21531981</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>L</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>Kullberg</surname><given-names>B-J</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes</article-title><source>Cell Host &amp; Microbe</source><volume>12</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.06.006</pub-id><pub-id pub-id-type="pmid">22901542</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinold</surname><given-names>J</given-names></name><name><surname>Farahpour</surname><given-names>F</given-names></name><name><surname>Schoerding</surname><given-names>A-K</given-names></name><name><surname>Fehring</surname><given-names>C</given-names></name><name><surname>Dolff</surname><given-names>S</given-names></name><name><surname>Konik</surname><given-names>M</given-names></name><name><surname>Korth</surname><given-names>J</given-names></name><name><surname>van Baal</surname><given-names>L</given-names></name><name><surname>Buer</surname><given-names>J</given-names></name><name><surname>Witzke</surname><given-names>O</given-names></name><name><surname>Westendorf</surname><given-names>AM</given-names></name><name><surname>Kehrmann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The fungal gut microbiome exhibits reduced diversity and increased relative abundance of ascomycota in severe COVID-19 illness and distinct interconnected communities in SARS-CoV-2 positive patients</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>12</volume><elocation-id>848650</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.848650</pub-id><pub-id pub-id-type="pmid">35521219</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>L</given-names></name><name><surname>Drinkwater</surname><given-names>CC</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Köntgen</surname><given-names>F</given-names></name><name><surname>Nicola</surname><given-names>NA</given-names></name><name><surname>Begley</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5</article-title><source>PNAS</source><volume>92</volume><fpage>9565</fpage><lpage>9569</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.21.9565</pub-id><pub-id pub-id-type="pmid">7568173</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roquilly</surname><given-names>A</given-names></name><name><surname>Jacqueline</surname><given-names>C</given-names></name><name><surname>Davieau</surname><given-names>M</given-names></name><name><surname>Mollé</surname><given-names>A</given-names></name><name><surname>Sadek</surname><given-names>A</given-names></name><name><surname>Fourgeux</surname><given-names>C</given-names></name><name><surname>Rooze</surname><given-names>P</given-names></name><name><surname>Broquet</surname><given-names>A</given-names></name><name><surname>Misme-Aucouturier</surname><given-names>B</given-names></name><name><surname>Chaumette</surname><given-names>T</given-names></name><name><surname>Vourc’h</surname><given-names>M</given-names></name><name><surname>Cinotti</surname><given-names>R</given-names></name><name><surname>Marec</surname><given-names>N</given-names></name><name><surname>Gauttier</surname><given-names>V</given-names></name><name><surname>McWilliam</surname><given-names>HEG</given-names></name><name><surname>Altare</surname><given-names>F</given-names></name><name><surname>Poschmann</surname><given-names>J</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name><name><surname>Asehnoune</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis</article-title><source>Nature Immunology</source><volume>21</volume><fpage>636</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0673-x</pub-id><pub-id pub-id-type="pmid">32424365</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Nobs</surname><given-names>SP</given-names></name><name><surname>Kurrer</surname><given-names>M</given-names></name><name><surname>Rehrauer</surname><given-names>H</given-names></name><name><surname>Thiele</surname><given-names>C</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages</article-title><source>Nature Immunology</source><volume>15</volume><fpage>1026</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1038/ni.3005</pub-id><pub-id pub-id-type="pmid">25263125</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirey</surname><given-names>KA</given-names></name><name><surname>Perkins</surname><given-names>DJ</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Fernando</surname><given-names>LR</given-names></name><name><surname>Gusovsky</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>JCG</given-names></name><name><surname>Vogel</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Influenza “Trains” the host for enhanced susceptibility to secondary bacterial infection</article-title><source>mBio</source><volume>10</volume><elocation-id>e00810-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00810-19</pub-id><pub-id pub-id-type="pmid">31064834</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title><source>Science</source><volume>339</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1232458</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>T</given-names></name><name><surname>Cheung</surname><given-names>CP</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Yeoh</surname><given-names>YK</given-names></name><name><surname>Niu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Chan</surname><given-names>PKS</given-names></name><name><surname>Chan</surname><given-names>FKL</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Population-level configurations of gut mycobiome across 6 Ethnicities in urban and rural China</article-title><source>Gastroenterology</source><volume>160</volume><fpage>272</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.09.014</pub-id><pub-id pub-id-type="pmid">32956679</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Acute lung injury caused by sepsis: how does it happen?</article-title><source>Frontiers in Medicine</source><volume>10</volume><elocation-id>1289194</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1289194</pub-id><pub-id pub-id-type="pmid">38076268</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szóstak</surname><given-names>N</given-names></name><name><surname>Handschuh</surname><given-names>L</given-names></name><name><surname>Samelak-Czajka</surname><given-names>A</given-names></name><name><surname>Tomela</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Pruss</surname><given-names>Ł</given-names></name><name><surname>Milanowska-Zabel</surname><given-names>K</given-names></name><name><surname>Kozlowski</surname><given-names>P</given-names></name><name><surname>Philips</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Host factors associated with gut mycobiome structure</article-title><source>mSystems</source><volume>8</volume><elocation-id>e0098622</elocation-id><pub-id pub-id-type="doi">10.1128/msystems.00986-22</pub-id><pub-id pub-id-type="pmid">36786595</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>BP</given-names></name><name><surname>Vĕtvicka</surname><given-names>V</given-names></name><name><surname>Pitman</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>RC</given-names></name><name><surname>Ross</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18)</article-title><source>Journal of Immunology</source><volume>156</volume><fpage>1235</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">8558003</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>GS</given-names></name><name><surname>Booth</surname><given-names>H</given-names></name><name><surname>Petit</surname><given-names>SJ</given-names></name><name><surname>Potton</surname><given-names>E</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name><name><surname>Miller</surname><given-names>RF</given-names></name><name><surname>Chain</surname><given-names>BM</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulation</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e40348</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040348</pub-id><pub-id pub-id-type="pmid">22768282</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>KA</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Downey</surname><given-names>J</given-names></name><name><surname>Chronopoulos</surname><given-names>J</given-names></name><name><surname>Lapshina</surname><given-names>E</given-names></name><name><surname>Tsai</surname><given-names>O</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>BCG immunization induces CX3CR1<sup>hi</sup> effector memory T cells to provide cross-protection via IFN-γ-mediated trained immunity</article-title><source>Nature Immunology</source><volume>25</volume><fpage>418</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01739-z</pub-id><pub-id pub-id-type="pmid">38225437</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuscan</surname><given-names>P</given-names></name><name><surname>Kischkel</surname><given-names>B</given-names></name><name><surname>Hatzioannou</surname><given-names>A</given-names></name><name><surname>Markaki</surname><given-names>E</given-names></name><name><surname>Sarlea</surname><given-names>A</given-names></name><name><surname>Tintoré</surname><given-names>M</given-names></name><name><surname>Cuñé</surname><given-names>J</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>de Lecea</surname><given-names>C</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Potent induction of trained immunity by <italic>Saccharomyces cerevisiae</italic> β-glucans</article-title><source>Frontiers in Immunology</source><volume>15</volume><elocation-id>1323333</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1323333</pub-id><pub-id pub-id-type="pmid">38415247</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs</article-title><source>Nature Immunology</source><volume>24</volume><fpage>423</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01428-x</pub-id><pub-id pub-id-type="pmid">36807642</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wengner</surname><given-names>AM</given-names></name><name><surname>Pitchford</surname><given-names>SC</given-names></name><name><surname>Furze</surname><given-names>RC</given-names></name><name><surname>Rankin</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation</article-title><source>Blood</source><volume>111</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-07-099648</pub-id><pub-id pub-id-type="pmid">17928531</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Vetvicka</surname><given-names>V</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Hanikýrová</surname><given-names>M</given-names></name><name><surname>Mayadas</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells</article-title><source>Journal of Immunology</source><volume>162</volume><fpage>2281</fpage><lpage>2290</lpage><pub-id pub-id-type="pmid">9973505</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Mindrinos</surname><given-names>MN</given-names></name><name><surname>Seok</surname><given-names>J</given-names></name><name><surname>Cuschieri</surname><given-names>J</given-names></name><name><surname>Cuenca</surname><given-names>AG</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Hayden</surname><given-names>DL</given-names></name><name><surname>Hennessy</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>Minei</surname><given-names>JP</given-names></name><name><surname>Bankey</surname><given-names>PE</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Sperry</surname><given-names>J</given-names></name><name><surname>Nathens</surname><given-names>AB</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>West</surname><given-names>MA</given-names></name><name><surname>Brownstein</surname><given-names>BH</given-names></name><name><surname>Mason</surname><given-names>PH</given-names></name><name><surname>Baker</surname><given-names>HV</given-names></name><name><surname>Finnerty</surname><given-names>CC</given-names></name><name><surname>Jeschke</surname><given-names>MG</given-names></name><name><surname>López</surname><given-names>MC</given-names></name><name><surname>Klein</surname><given-names>MB</given-names></name><name><surname>Gamelli</surname><given-names>RL</given-names></name><name><surname>Gibran</surname><given-names>NS</given-names></name><name><surname>Arnoldo</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Calvano</surname><given-names>SE</given-names></name><name><surname>McDonald-Smith</surname><given-names>GP</given-names></name><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>Cobb</surname><given-names>JP</given-names></name><name><surname>Warren</surname><given-names>HS</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name><name><surname>Herndon</surname><given-names>DN</given-names></name><name><surname>Lowry</surname><given-names>SF</given-names></name><name><surname>Maier</surname><given-names>RV</given-names></name><name><surname>Davis</surname><given-names>RW</given-names></name><name><surname>Tompkins</surname><given-names>RG</given-names></name><collab>Inflammation and Host Response to Injury Large-Scale Collaborative Research Program</collab></person-group><year iso-8601-date="2011">2011</year><article-title>A genomic storm in critically injured humans</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>2581</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1084/jem.20111354</pub-id><pub-id pub-id-type="pmid">22110166</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Niu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mechanisms of sepsis-induced acute lung injury and advancements of natural small molecules in its treatment</article-title><source>Pharmaceuticals</source><volume>17</volume><elocation-id>472</elocation-id><pub-id pub-id-type="doi">10.3390/ph17040472</pub-id><pub-id pub-id-type="pmid">38675431</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Schorey</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria</article-title><source>Blood</source><volume>108</volume><fpage>3168</fpage><lpage>3175</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-024406</pub-id><pub-id pub-id-type="pmid">16825490</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>CARD9 Syk-dependent and Raf-1 Syk-independent signaling pathways in target recognition of Candida albicans by Dectin-1</article-title><source>European Journal of Clinical Microbiology &amp; Infectious Diseases</source><volume>30</volume><fpage>303</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1007/s10096-010-1103-z</pub-id><pub-id pub-id-type="pmid">21108038</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Haddadi</surname><given-names>S</given-names></name><name><surname>Barra</surname><given-names>NG</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Damjanovic</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dvorkin-Gheva</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Schertzer</surname><given-names>JD</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity</article-title><source>Cell</source><volume>175</volume><fpage>1634</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.042</pub-id><pub-id pub-id-type="pmid">30433869</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahalka</surname><given-names>S</given-names></name><name><surname>Starkl</surname><given-names>P</given-names></name><name><surname>Watzenboeck</surname><given-names>ML</given-names></name><name><surname>Farhat</surname><given-names>A</given-names></name><name><surname>Radhouani</surname><given-names>M</given-names></name><name><surname>Deckert</surname><given-names>F</given-names></name><name><surname>Hladik</surname><given-names>A</given-names></name><name><surname>Lakovits</surname><given-names>K</given-names></name><name><surname>Oberndorfer</surname><given-names>F</given-names></name><name><surname>Lassnig</surname><given-names>C</given-names></name><name><surname>Strobl</surname><given-names>B</given-names></name><name><surname>Klavins</surname><given-names>K</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Sanin</surname><given-names>DE</given-names></name><name><surname>Grzes</surname><given-names>KM</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Gorki</surname><given-names>A-D</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Trained immunity of alveolar macrophages requires metabolic rewiring and type 1 interferon signaling</article-title><source>Mucosal Immunology</source><volume>15</volume><fpage>896</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/s41385-022-00528-5</pub-id><pub-id pub-id-type="pmid">35856089</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zervopoulou</surname><given-names>E</given-names></name><name><surname>Grigoriou</surname><given-names>M</given-names></name><name><surname>Doumas</surname><given-names>SA</given-names></name><name><surname>Yiannakou</surname><given-names>D</given-names></name><name><surname>Pavlidis</surname><given-names>P</given-names></name><name><surname>Gasparoni</surname><given-names>G</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Filia</surname><given-names>A</given-names></name><name><surname>Gakiopoulou</surname><given-names>H</given-names></name><name><surname>Banos</surname><given-names>A</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Boumpas</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Enhanced medullary and extramedullary granulopoiesis sustain the inflammatory response in lupus nephritis</article-title><source>Lupus Science &amp; Medicine</source><volume>11</volume><elocation-id>e001110</elocation-id><pub-id pub-id-type="doi">10.1136/lupus-2023-001110</pub-id><pub-id pub-id-type="pmid">38471723</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gut-lung crosstalk in sepsis-induced acute lung injury</article-title><source>Frontiers in Microbiology</source><volume>12</volume><elocation-id>779620</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.779620</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102068.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kaufmann</surname><given-names>Eva</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Queen's University</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study advances our understanding of maladaptive innate immune training. The experimental evidence supporting the conclusions is <bold>convincing</bold> and the expert reviewers strongly endorse the manuscript. The work will be of high interest to both researchers in the trained immunity field and clinician scientists.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102068.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The concept that trained immunity, as defined, can be beneficial to subsequent immune challenges is important in the broad context of health and disease. The significance of this manuscript is the finding that trained immunity is actually a two-edged sword, herein, detrimental in the context of LPS-induced Acute Lung Injury that is mediated by AMs.</p><p>Strengths:</p><p>Several lines of evidence in different mouse models support this conclusion. The postulation that differences in immune responses in individuals is linked to differences in the mycobiome and consequent B-glucan makeup is provocative.</p><p>Weaknesses:</p><p>However, the findings that the authors state are relevant to sepsis are actually confined to a specific lung injury model and not classically-defined sepsis, the ontogeny of the reprogrammed AMs is uncertain, and links in the proposed signaling pathways need to be strengthened.</p><p>Comments on the latest version:</p><p>The manuscript is improved with further clarifications and additional experimentation. My prior concerns are addressed.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102068.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Prével et al. present an in vivo study in which they reveal an interesting aspect of β-glucan, a known inducer of enhanced immune responses termed trained immunity in sterile inflammation. The authors can show that β-glucan's can reprogram alveolar macrophages (AMs) in the lungs through neutrophils and IFNγ signaling and independent of Dectin1. This reprogramming occurs at both transcriptional and metabolic levels. After β-glucan training, LPS induced sterile inflammation exacerbated acute lung injury via enhanced immunopathology. These findings highlight a new aspect of β-glucan's role in trained immunity and its potential detrimental effects when enhanced pathogen clearance is not required.</p><p>Strengths:</p><p>- This manuscript is well-written and effectively conveys its message.</p><p>- The authors provide important evidence that β-glucan training is not solely beneficial but depending on the context can also enhance immunopathology. This will be important to the field for two reasons. It shows again that trained immunity can also be harmful. Jentho et al. 2021 had already provided further evidence for this aspect. And it highlights anew that LPS application is an insufficient infection model.</p><p>Original weaknesses noted:</p><p>- Only a little physiological data from the in vivo models is provided.</p><p>- Effects in histology appear to be rather weak.</p><p>Comments on latest version:</p><p>The authors have revised the new version according to my suggestions or responded in a sufficient manner to my requests, with one exception. I recommend to rename TNF as explained by Grimstad in JAMA Dermatol. 2016;152(5):557.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102068.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prevel</surname><given-names>Renaud</given-names></name><role specific-use="author">Author</role><aff><institution>Université de Bordeaux</institution><addr-line><named-content content-type="city">Pessac</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Pernet</surname><given-names>Erwan</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Kim A</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Sadek</surname><given-names>Abderrahmane</given-names></name><role specific-use="author">Author</role><aff><institution>Université Moulay Ismail de Meknes</institution><addr-line><named-content content-type="city">Meknès</named-content></addr-line><country>Morocco</country></aff></contrib><contrib contrib-type="author"><name><surname>Sadeghi</surname><given-names>Mina</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Lapshina</surname><given-names>Elizabeth</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Jurado</surname><given-names>Leonardo F</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Kristof</surname><given-names>Arnold S</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University Health Centre</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Moumni</surname><given-names>Mohieddine</given-names></name><role specific-use="author">Author</role><aff><institution>Université Moulay Ismail de Meknes</institution><addr-line><named-content content-type="city">Meknès</named-content></addr-line><country>Morocco</country></aff></contrib><contrib contrib-type="author"><name><surname>Poschmann</surname><given-names>Jeremie</given-names></name><role specific-use="author">Author</role><aff><institution>University of Nantes</institution><addr-line><named-content content-type="city">Nantes</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Divangahi</surname><given-names>Maziar</given-names></name><role specific-use="author">Author</role><aff><institution>McGill University</institution><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The concept that trained immunity, as defined, can be beneficial to subsequent immune challenges is important in the broad context of health and disease. The significance of this manuscript is the finding that trained immunity is actually a two-edged sword, herein, detrimental in the context of LPS-induced Acute Lung Injury that is mediated by AMs.</p><p>Strengths:</p><p>Several lines of evidence in different mouse models support this conclusion. The postulation that differences in immune responses in individuals are linked to differences in the mycobiome and consequent B-glucan makeup is provocative.</p><p>Weaknesses:</p><p>The findings that the authors state are relevant to sepsis, are actually confined to a specific lung injury model and not classically-defined sepsis. In addition, the ontogeny of the reprogrammed AMs is uncertain. Links in the proposed signaling pathways need to be strengthened.</p><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>Prével et al. present an in vivo study in which they reveal an interesting aspect of β-glucan, a known inducer of enhanced immune responses termed trained immunity in sterile inflammation. The authors can show, that β-glucan's can reprogram alveolar macrophages (AMs) in the lungs through neutrophils and IFNγ signaling and independent of Dectin1. This reprogramming occurs at both transcriptional and metabolic levels. After β-glucan training, LPS-induced sterile inflammation exacerbated acute lung injury via enhanced immunopathology. These findings highlight a new aspect of β-glucan's role in trained immunity and its potential detrimental effects when enhanced pathogen clearance is not required.</p><p>Strengths:</p><p>(1) This manuscript is well-written and effectively conveys its message.</p><p>(2) The authors provide important evidence that β-glucan training is not solely beneficial, but depending on the context can also enhance immunopathology. This will be important to the field for two reasons. It shows again, that trained immunity can also be harmful. Jentho et al. 2021 have already provided further evidence for this aspect. And it highlights anew that LPS application is an insufficient infection model.</p><p>Weaknesses:</p><p>(1) Only a little physiological data is provided by the in vivo models.</p><p>(2) The effects in histology appear to be rather weak.</p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>The opening paragraph in the introduction focuses on sepsis. This is misleading since this manuscript does not address sepsis but rather intranasal-administered LPS-induced acute lung injury.</p></disp-quote><p>We are in total agreement with the reviewer and have modified the introduction to focus on acute lung injury with clinical relevance more associated to TLR4-mediated acute lung injury and lung inflammation.</p><disp-quote content-type="editor-comment"><p>The authors make definitive statements that AMs originate from fetal liver monocytes. However, it is well known that the ontogeny of AMs is complex and AMs can be populated, in part, from peripheral monocytes. The ontogeny of reprogrammed AMs was not addressed in this study but they may come from monocyte-derived AMs following B-glucan training (transfer of AMs into Csf2rb KO mice does not prove the contrary). In this regard, do, for example, the percentages of CD11b+ AMs change? More phenotyping of the control and reprogrammed AMs would enhance the interpretation of the findings.</p></disp-quote><p>The reviewer is correct that the ontogeny of AMs can be heterogenous, especially following a pulmonary challenge. In β-glucan-treated mice, Figure 1I shows no changes in frequency or number of AMs in the BAL. As the reviewer suggested, we repeated this experiment and incorporate more markers for AMs. New Supplementary Figure 1C shows the expression of CD11b on AMs (CD11c<sup>+</sup>SiglecF<sup>+</sup>) from control and β-glucan-treated mice. While the frequency increases with LPS administration, we show no difference between control and β-glucan groups suggesting β-glucan does not induce the expansion of monocyte-derived AMs. Additionally, in New Supplementary Figure 1D, we show the expression of AM-associated markers in order to better delineate their phenotype. We observed no differences in MHCII, CD169, CD64 and F4/80 in β-glucan-treated mice, but an increase in CD80<sup>+</sup> AMs following βglucan suggesting enhanced activation corroborating their proinflammatory phenotype. Collectively, these data indicate that while the frequency and number of either yolk-sac or BMderived AMs are unchanged in the β-glucan treated mice, the activation of AMs is enhanced after the systemic treatment with β-glucan.</p><disp-quote content-type="editor-comment"><p>The abstract seems to overpromise a bit. First, it mentions trained immunity and HSCs, but they don't seem to formally address either in the context of this model (there is reprogramming as assessed by transcriptome and metabolic analyses which is suggestive as stated by the authors, but do the changes overlap significantly with classically trained immunity?), and second, it links phenotypes together in a pathway(s) that they haven't actually interrogated - although they look at transcripts and do a seahorse assay they don't actually confirm that any of those findings are related to the increased response to LPS in vivo. The long discussion with all the caveats highlights these limitations, all relegated to future studies.</p></disp-quote><p>We thank the reviewer for this comment. In response, we have revised the abstract to more accurately highlight the key findings of this study. Specifically, we introduced the concept of central trained immunity to describe the phenomena commonly observed with β-glucan treatment, contrasting it with the peripheral trained immunity detailed in the manuscript.</p><p>The use of Csf2rb-/- mice to complement the clodronate approach is interesting (this approach has been used in the past with influenza virus). In addition to lacking AMs, these mice develop pulmonary alveolar proteinosis. Do the authors have histopathology from these mice in the current model? They mention PAP in the discussion.</p><p>Pulmonary alveolar proteinosis (PAP) typically develops in Csf2b-/- mice from 12 weeks of age onwards (Stanley et al., Proc Natl Acad Sci USA, 1994). However, in our model, mice were euthanized at 6 weeks, ensuring that pulmonary function and structure remained intact. A hallmark of PAP is the accumulation of protein, primarily surfactant, in BAL. To investigate this, we measured BAL protein concentration and observed no differences at baseline (Figure 2F). These findings were further supported by the absence of differences in BAL proinflammatory cytokine concentrations (Figure 2H).</p><disp-quote content-type="editor-comment"><p>A question about their BAL technique? In the control mice without glucan/LPS stimulation, only 40% of BAL cells are AMs and the total number of AMs (range of &lt;103 to 2-3 x 104) is at least 5-fold lower than typically seen in BALs from healthy mice (105), and there didn't seem to be many PMNs either. Are 60% of the BAL cells lymphocytes/ RBCs? Is it possible that overall AM numbers are changing, but CD11c/SiglecF-positive cell numbers stay the same (only assessed 2 markers)? More phenotyping would help.</p></disp-quote><p>We appreciate the reviewer’s comment and would like to clarify that alveolar macrophages (AMs) are presented in the manuscript as a frequency of viable cells rather than as a frequency of CD45<sup>+</sup> cells, to ensure consistency throughout the study. The remaining cells in the samples are likely epithelial cells and lymphocytes, as red blood cells are lysed during sample processing. For additional context, we now provide data showing AMs as a percentage of CD45<sup>+</sup> cells, which account for 80–90% of leukocytes. Furthermore, in New Supplementary Figure 1D, we highlight the expression of AM-associated markers to better define their phenotype. We observed no differences in MHCII, CD169, CD64, or F4/80 expression in βglucan-treated mice. However, there was an increase in CD80<sup>+</sup> AMs, indicating enhanced activation and corroborating their proinflammatory phenotype.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>AMs as percentage of CD45<sup>+</sup> cells.</title><p>Mice were treated with β-glucan for seven days. We show CD11c<sup>+</sup>SiglecF<sup>+</sup> cells in the bronchoalveolar lavage (BAL) as a percentage of CD45<sup>+</sup> cells (n=5).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102068-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Line 130-131. TNF is decreased and not pointed out.</p></disp-quote><p>In the poly(I:C) model, the difference in the BAL TNF concentration is not statistically different between naïve and trained mice due to high variability of data. The reviewer is correct that TNFα does not appear to reflect Poly(I:C)-mediated ALI. We have included this point in the revised manuscript (Line 146-148).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Suggestions:</p><p>(1) The authors provide evidence for enhanced ALI via different techniques, e.g. histology, vascular leakage, immune cell composition in BAL etc. It would be interesting to see whether there were any changes in the disease severity of ALI. If possible the authors could provide data for survival, temperature, weight, and/or glucose in the different groups.</p></disp-quote><p>Mice are extremely resistant to the pulmonary LPS model. We have previously assessed lethality of our LPS model, and all mice survive even with an increased intranasal dose of LPS 200μg (Pernet et al, Nature, 2023). To address the reviewer concerns, we next assessed the morbidity by monitoring weight loss following LPS challenge and showed β-glucan-treated mice exhibit a delayed recovery time after 4 days LPS treatment (New Supplementary Figure 1B).</p><disp-quote content-type="editor-comment"><p>(2) The authors show that ß-glucan mediated training enhances ALI. Conversely, the opposite, decreased immunopathology should be observed in case an LPS tolerance model would be used. I am wondering whether this has already been performed, given that the (LPS/immune)tolerance field is already older than the training field. If not, I suggest incorporating this feature in their discussion.</p></disp-quote><p>Thank you for this insightful comment. While LPS has long been recognized to induce tolerance, studies have also shown that intranasal exposure to ambient levels of LPS can induce alveolar macrophage (AM) training via type I interferon signaling (Zahalka et al., Mucosal Immunol, 2022). In contrast, Mason et al. demonstrated that systemic LPS stimulation induces tolerance through TNF-α signaling, resulting in diminished AM phagocytosis and superoxide production. This leads to reduced neutrophil recruitment and impaired bacterial clearance in a <italic>Pseudomonas aeruginosa</italic> pneumonia model (J Infect Dis, 1997). Furthermore, we recently reported that systemic administration of β-glucan induces central trained immunity, generating a distinct subset of regulatory neutrophils that promote disease tolerance against influenza viral infection (Khan et al., Nat Immunol, 2025). These findings highlight the complex and context-dependent interplay between training and tolerance. We have expanded on this point in the discussion section of the revised manuscript (Lines 289-297).</p><disp-quote content-type="editor-comment"><p>(3) The finding that trained immunity can exert not only beneficial effects but also enhance immunopathology is interesting and should be further explored. Already Jentho et al. (PNAS 2021) have shown that upon sterile inflammation as imposed by LPS, (heme) training can lead to enhanced mortality. This might be a relevant trade-off in trained immunity since no beneficial resistance effect by pathogen killing can be obtained. It would be interesting to see, in their model, whether heme would also enhance ALI after intranasal LPS application. Or at least, can the authors discuss this finding more, also in relation to the already published evidence?</p></disp-quote><p>Thank you for raising this interesting point, which is indeed relevant to our study. Jentho et al. demonstrated that training by heme can be beneficial in combating infectious challenges but can have deleterious effects in the context of sterile inflammation. The concept of endogenous training agents like heme, with their diverse effects on immune cells, aligns well with our βglucan model, particularly given the high prevalence of fungal agents in the microbiome.</p><p>While investigating the effects of heme on alveolar macrophages would certainly be intriguing, Jentho and colleagues have already reported the maladaptive effects of heme, such as tissue damage, during sterile LPS-induced inflammation. As such, these findings might be redundant in the context of our model. However, we have drawn a relevant parallel and expanded on this discussion in the revised manuscript (Lines 382-385).</p><disp-quote content-type="editor-comment"><p>(4) It is not clear how the histologies were evaluated. This is a field of great subjectivity. The authors should describe it in more detail. The best option would have been a blinded observer. Was this done?</p></disp-quote><p>Histology samples were evaluated according to ATS 2011 guidelines regarding “Features and measurements of experimental acute lung injury in animals” by a blinded pathologist. We have specified this in the methods of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Minor:</p><p>(1) Line 108 and ff. Please change TNF, not TNFa</p></disp-quote><p>Since we used an ELISA specific for TNF-α rather than general TNF, it is more accurate to refer to it as TNF-α.</p><disp-quote content-type="editor-comment"><p>(2) Line 513 and ff. Please use Greek letters when appropriate, e.g. IFN-γ not IFNg.</p></disp-quote><p>Thank you for pointing out these mistakes, we rectified these in the text.</p></body></sub-article></article>